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ABSTRACT

During the late stages of breast cancer progression, breast cancer cell growth
switches from steroid hormone to growth factor dependence, and it is assumed that
invasive breast cancers are growth factor receptor positive and estrogen hormone
resistant. The cellular arachidonic acid (AA) pathway is upregulated in a variety of
cancer types, and it may play an important role in the growth regulation of breast cancer
cells.
Recent evidence suggests that beta-adrenergic receptors (β-ARs) are expressed in
some estrogen receptor (ER) negative breast cancers and that beta agonists not only can
trigger AA release via the activation of cytosolic PLA2 or MAPK but also stimulate DNA
synthesis in ER (-) breast cancers. AA is metabolized to prostaglandins and leukotrienes
by cyclooxygenases (COX-1, 2) and 5-lipoxygenase (5-LOX), respectively. COX-1 is
constitutively expressed and required for the homeostatic function, whereas COX-2 is
overexpressed during pathological conditions and cancer.

It is well documented that

COX-2 and 5-LOX are overexpressed in ER (-) breast cancers.

Additionally, in many

cell types there is a link between G-protein inwardly rectifying potassium channel 1
(GIRK1) and beta-adrenergic receptor pathways.

A recent report has demonstrated

overexpression of GIRK1 in metastatic breast carcinomas.
Using thymidine incorporation assays, this study shows that antagonists of β-AR,
COX, 5-LOX or potassium channels in vitro decreased cell proliferation in both ER (-)
v

and (+) breast cancer cell lines. The general β-blocker propranolol was more effective
than the selective β2-antagonist ICI 118,551 or the selective β1-antagonist atenolol. ER
(+) cell lines generally were more responsive to the β1-antagonist atenolol whereas ER () cell lines were more responsive to the β2-antagonists ICI 118,551. The β-1/ 2- agonist
isoproterenol significantly increased DNA synthesis in only ER (-) cell lines.

The

reduction in DNA synthesis caused by the 5-LOX inhibitor MK-886 and non-specific
LOX inhibitor NDGA was significantly higher in ER (-) cell lines than in ER (+) cell
lines.

The COX 1/2 inhibitor aspirin and the specific COX-2 inhibitor meloxicam

reduced DNA synthesis in both cell lines. The potassium (K+) channel blocker quinidine
inhibited DNA synthesis in both cell lines, and the ER (-) cell line MDA-MB-453 was
more sensitive to this effect. RT-PCR experiments showed that the ER (-) cell line MDAMB-453 expressed mRNA for the GIRK1 channel. In summary, our study suggests a
link among beta-adrenergic receptor, potassium channel and AA cascade.
The observed ability of COX inhibitors, 5-LOX inhibitors, β-adrenergic blockers
and K+ channel blockers to suppress the growth and proliferation of the a subset of
human breast cancer cells lines is an important finding that provides the basis for the
exploration of such agents in the clinical management and prevention of breast cancer.
Because these inhibitors are already widely used for the treatment of various diseases
they can immediately be used in clinical trials with breast cancer patients. In particular
the β-ARs represent a promising new target for the development of new drug candidates
with potential application in the clinical fields because a wealth of information is already
available on the biochemical and molecular events underlying signaling by these
receptors.
vi
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CHAPTER 1: INTRODUCTION
Modulators of Breast Cancer Risk:
Breast cancer is the leading type of cancer in women and ranks second after lung
cancer as the cause of cancer death.

Estimates from the American Cancer Society

indicate that about 192,200 new cases of invasive breast cancer will be diagnosed among
women in the United States and more than 40,000 deaths will be attributed to this disease
in 2001.

In the State of Tennessee, about 4,200 new breast cancer cases will be

diagnosed in females and, the estimated number of deaths from breast cancer will be
about 900 in 2001 (1,2).
A large number of risk factors for breast cancer have been identified (Table 1),
even though some of these reports have yielded contradictory results (1-11). Of
immediate relevance to this project are the findings that smoking and drinking as well as
caffeine are risk factors for breast cancer whereas the long-term treatment of arthritis
with non-steroidal anti-inflammatory agents (NSAIDS) has protective effects.

Tobacco

smoke contains the carcinogenic nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1butanone (NNK), which is a high affinity beta-adrenergic agonist while nicotine
stimulates the release of the physiologic beta-adrenergic agonists epinephrine and
norepinephrine from the adrenal medulla (12-14).

Studies in human adenocarcinomas

of lungs and pancreas have shown that beta-adrenergic stimulation by NNK or classic
beta-adrenergic agonists increases DNA synthesis and arachidonic acid (AA) release
(15).

If similar pathways are expressed in adenocarcinomas of the breast, the chronic

1

Table 1: The important risk factors identified in breast cancer:
______________________________________________________________________
1. Female Gender
2. Higher incidence in Western nations
3. Black Women
4. Previous breast cancers or carcinoma in situ or atypical hyperplasia
5. Family History
6. Hereditary Breast Cancer
BRCA1 (Breast cancer associated gene 1)
BRCA2 (Breast cancer associated gene 2)
BRCA3 (Breast cancer associated gene 3)
P53
Ataxia-telangiectasia
7.Estrogens (Contradictory Data)
The longer a woman is exposed to estrogen the higher is the risk of breast cancer
Early Menstruation (Before age 12)
Late Menopause (After age 55)
Having no children or having them after age of 30
Pregnancy
Miscarriage and Abortions
Subsequent Births
8.HRT (Hormone Replacement Therapy)
Estrogen alone
Estrogen with Progesterone
Tamoxifen
_____________________________________________________________________

2

Table 1: (continued) The important risk factors identified in breast cancer:
______________________________________________________________________
9.Chemicals that mimic estrogens
(Xenoestrogens: Dioxin, pesticides, plasticizers, and polystyrenes)
10.Hormonal contraceptives
11.Heavy Dense Bones – Estrogen helps build bone mass.
12.Chemical carcinogens: Polycyclic Aromatic Hydrocarbons
13.Radiation
14.Alcohol consumption
15.Reduced Melatonin-Higher breast cancer incidence in flight attendant
16.Postmenopausal obesity
17. A diet high in fat:
a) Linoleic Acid (ω-6 –polyunsaturated fatty acids i.e., soy, corn, sunflower and
other vegetable oil)—BAD FAT.
b) Linolenic acid (ω-3-monounsaturated fatty acids i.e., fish, olive, canola oils)GOOD FAT.
________________________________________________________________________
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stimulation by beta- adrenergic agonists contained in tobacco may contribute
significantly to the increased risk for breast cancer observed in smokers.

Moreover,

ethanol and caffeine both increase intracellular levels of cyclic-adenosine monophosphate (c-AMP), an effect that enhances beta-adrenergic signaling (16-18).

Beta-

adrenergic stimulation causes the release of arachidonic acid in human mammary, human
pulmonary and pancreatic adenocarcinoma cell lines, resulting increased DNA synthesis
and cell number that were significantly reduced by beta-blockers or NSAIDs that block
AA metabolism by cyclooxygenase (COX) enzyme (15,19-29).
n-6 polyunsaturated fatty acid (n-6 PUFA) linoleic acid (LA).

AA is derived from the
High levels of n-6 PUFA

in the diet have been associated with an increased risk for the development of breast
cancer and promote the development of breast cancer in animal models via increased
synthesis of eicosanoids.

By contrast, n-3 PUFAs have suppressive effects on the

development of breast cancer (30,31).

Unlike 2-series prostaglandins (PGs) and 4-series

leukotrienes (LTs) produced by the tumor promoter n-6 PUFAs, the n-3 PUFAs (alpha
linolenic acid) produces 3-series PGs and 5-series LTs that do not promote cancer
formation (32,33).

Linoleic acid (LA) stimulated the growth of two ER (-) breast cancer

cell lines, MDA-MB-231 and MDA-MB-435, in athymic nude mice and tumor
progression was suppressed by the COX inhibitor indomethacin (33).
The n-3 PUFAs are found mainly in fish oil, olive oil, flaxseed oil, canola oil, and
marine food while n-6 PUFAs are found in soy, safflower, sunflowers and corn oil.

The

high proportion of seafood consumed by Asian women is responsible for their lower risk
to develop breast cancer.

The n-3 PUFAs comprise α-linolenic acid, eicosapentanoic,

and docosahexanoic acids and have been shown to suppress breast cancer.
4

The n-6

PUFAs, on the other hand, consist of linoleic, and arachidonic acids and may induce
breast cancer formation (34-36).

The dietary ratio of n-6: n-3 is an important factor that

determines the risk for breast cancer development (34). The presence of n-3 fatty acids
decreases the eicosanoids production both through competition with AA as a substrate for
COX-2 and through the inhibition of the conversion of LA to AA (32).
Collectively, these epidemiological and experimental data provide the rational for
the current project, which focuses on the role of beta-adrenergic, AA-mediated growth
regulation of human breast cancer cell lines.

Growth-Regulating Pathways Expressed in Breast Epithelia and Breast Cancer:
Estrogen (E) plays an important role in human breast development and in the
normal physiological functioning of the adult breast tissue because it is required for
normal ductal development and induction of progesterone (PR) expression (1,37-39)
(Figure 1).

Expression levels of estrogen receptors (ERs) are high in some breast

cancers while being low in normal breast epithelium adjacent to the malignant lesions
(40,41).

The connection between estrogen and breast cancer has been recognized for

more than 100 years (42).

The cumulative lifetime exposure to endogenous (and in a

small degree to exogenous) estrogen is one of the important determinants of breast cancer
risk.

In animal model systems, estrogen induced and promoted mammary tumors, and

removing animals’ ovaries suppresses the effect of estrogen (37).

Two clinically

different types of breast cancer are recognized: breast cancers that express the ER (ER
(+) or estrogen-responsive) and breast cancers that do not express the ER (ER (-).

5

(a)
Normal Mammary Epithelium
Estrogen (E)

ER

Paracrine

Ductal Growth

PR

Differentiation
(b)
BREAST CANCER
Aromatase
Androgen

Estrogen (E)
ER

c-myc, Cyclin D1

PR

Growth and Proliferation

Differentiation

Figure 1: The role of estrogen and the ER on breast development and cancer. In normal
breast tissue, estrogen induces ductal growth via a paracrine loop and progesterone (PR)
expression so that mammary differentiation may occur (a). However, during breast
cancer development, estrogen blocks differentiation and induces c-myc and cyclin D1
genes to stimulate growth and proliferation (b).
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Immunohistochemical studies have shown that about 70 % of breast cancers stain
positively for ER (43).

These tumors are often more differentiated, less invasive and

respond to anti-estrogen therapy.

On the other hand, nearly 30 % of breast cancers have

no ER as demonstrated by immunohistochemical and radio-ligand binding assay.

These

tumors tend to be more aggressive and rarely respond to hormonal therapies since they
may grow in the absence of estrogen (44).
The mechanism how estrogen contributes to the development of breast cancer is
poorly understood. Alkylation of cellular molecules and the generation of active radicals
that damage DNA by estrogen and/or its metabolites may be involved (42,45-47).
Estrogen has direct and indirect proliferative effects as demonstrated in studies using
human breast cancer cell lines.

Direct action may occur through the activation of

oncogenes, inactivation of tumor suppressor genes and induction of genes or proteins
involved in DNA synthesis, whereas indirect action may occur through the interaction
with peptide and non-peptide growth factors (42).
In addition to the nuclear ER through which estrogen exerts its effect on DNA, a
membrane estrogen receptor (mER) has been recently identified through which estrogen
may interact with tyrosine kinase receptors in the ras / raf / MAPK (Mitogen activated
protein kinase) signaling pathway (48-50).

This mER operates as a G-protein coupled

receptor (GPCR) that has been shown to mediate Ca+2 mobilization and Ca+2 influx in
mouse macrophages in vitro (51).

Consistent with this, E binds to mER to activate a

variety of signaling cascades: a) stimulation of the AC-c-AMP-PKA (protein kinase –A)
pathway by inducing GS subunits of G-proteins, b) activation of PLC (phospholipase-C)
resulting in increases in intracellular calcium (Ca+2) concentration and protein kinase-C
7

(PKC) through the stimulation of Gq subunits of G-proteins, c) activation of the
MAPK/ERK (extracellular regulated kinase) pathway through Src or Ras, d) activation of
fos expression through ERK (52).
Locally acting polypeptide hormones or growth factors modulate the regulation of
breast tissue by estrogen and progesterone. These growth factors regulate cell growth by
activating intracellular signaling pathways after binding to high affinity tyrosine kinase
receptors on the cell surface (Figure: 2).

Among these, the MAPK pathway plays an

important role in the transduction of mitogenic signals initiated by growth factors acting
on a variety of cell surface receptors. MAP kinases are regulated through many protein
phosphorylation cascades.
Several stimulatory growth factors are found in breast cancers including,
epidermal growth factor (EGF), transforming growth factor alpha (TGFα), insulin growth
factor-1/2 (IGF- 1/2), platelet derived growth factor-A/B (PDGF- A/B), fibroblast growth
factor (FGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor,
(HGF) and mammary derived growth factor-1 (MDGF-1) (53-57). The EGF receptor
(EGFR) is a 170 kDa transmembrane receptor with tyrosine kinase activity, which has
several ligands including EGF, amphiregulin (AR) and TGFα (53). EGF and the EGFR
are frequently over-expressed in ER (-) breast cancers. When the ER (+) human breast
cancer cell line MCF-7 was transfected with an anti-sense estrogen receptor RNA, the ER
levels decreased whereas EGFR expression increased, suggesting that loss of expression
of ER may render breast cancer cells to have concomitant EGFR increases or activate
EGFR expression by inducing cellular cascades (58).

8

Figure 2: Several peptide growth factors activate the MAPK pathway in ER(-) breast
cancer cells. The MAPK pathway can also be stimulated by mutant Ras and by autocrine
and paracrine growth factor loops implicated in cancer growth.
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Agents inducing c-AMP stimulation (okadaik acid, forskolin) stimulate ligandindependent transcriptional activation of the ER and synergize with the ER-mediated
activation (59). Cross talk between the ER and PKA pathway has been observed and
stimulation of PKA activates the agonist activity of antiestrogens in ER (+) breast cancers
(59-62). Up-regulation of PKA activity leads to ligand-independent activation of ER and
increased phosphorylation at the activating factor-1 (AF-1) site of the ER gene (63-65).
On the other hand, prolonged exposure of the ER (+) human breast cancer cell
line MCF-7 to high c-AMP levels led to a reduction in the number of estrogen receptors
(66).

These findings suggest that PKA or c-AMP activators and inhibitors may

modulate the development of breast cancer because estrogen may act through the c-AMP
system to regulate c-AMP-mediated gene expression.

This may have potential

importance in the beta-adrenergic regulation of breast cancers investigated in this project,
as these receptors often activate cAMP/PKA signaling pathway.
The arachidonic acid (AA)-metabolizing enzymes cyclooxygenase-2 (COX-2)
and lipoxygenases (LOXs) are frequently over-expressed in ER (-) breast cancers,
suggesting a role of the AA-cascade in the development of this malignancy (22,23,27,6770). Specific AA metabolites have been reported to modulate the proliferation and
development of several cancers, including breast cancer (Figure: 3).

Activation of

phospholipase-A2 (cPLA2) represents the rate- limiting step in the production of different
eicosanoids because the resting level of AA is normally low within the cells (71,72).
The cPLA2 translocates from the cytosol to the endoplasmic reticulum and perinuclear
membranes where COXs and LOXs are localized (72,73).
expressed in pancreatic and lung adenocarcinoma cells (74,75).
10

PLA2 isoforms are overPhosphorylation of

Figure 3: The Arachidonic acid (AA) cascade and several chemicals (in brackets)
inhibiting the formation of AA metabolites.
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cPLA2 by oncogenic Ras and MAP kinase ERK2 in cells over-expressing cPLA2 and
ERK2 may cause the release of AA from membrane phospholipids (71,76). AA induced
MAPK pathway in the ER (-) human breast cancer cell line, MDA-MB-435 (21). The
interaction of EGF with its receptors in breast cancer cells can also lead to the hydrolysis
of phospholipids and release of fatty acids, such as AA. Several LOX products not only
have mitogenic effect but they also activate several oncogenes (77-79).
The induction of AA metabolism is a characteristic response to tissue damage and
irritation and may contribute to epithelial tumor promotion (22,23).

AA has been

indicated as a potent second messenger responsible for a number of cellular events.

It

activates PKC, MAPK, and PKA; synthesizes heat shock proteins; activates
sphingomyelinases leading to apoptosis; induces immunoglobulin G (IgG)-mediated
phagocytosis; and activates NAPDH oxidase resulting in the production of the superoxide
anion (80). AA has been shown to increase cellular c-AMP levels in primary epithelial
cell cultures taken from C3H mouse mammary tumors (29). AA is also subject to nonenzymatic, free radical oxidation to bioactive isoprostanes and isoleukotrienes (81).
Fatty acids may also be second messenger molecules for the modulation of ion channels.
This might involve direct interaction of AA with the ion channels or alteration of ion
channel interactions with the plasma membrane.

AA and PGs have been shown to

modulate ion channels, including Ca+2, K+1, Cl-1 and Na+1 channels.

For example, AA

caused the release of Ca+2 from intracellular stores, activated Ca+2 influx from the
membrane channels and activated potassium channels in smooth and heart muscle cells
(82,83).

12

NSAIDs inhibit both COX isoenzymes, and regularly taking NSAIDs provides a
40-50% decrease in the risk of death by colon cancer (24). A link between the effects
NSAIDs and COX-2 protein amplification has been suggested in some studies in that
ibuprofen not only suppressed the proliferation of mammary tumors but also inhibited
both the production of PGs and the expression of COX-2 protein in mammary tumors
(84,85).
There are two isoforms of COX: COX-1 (a constitutive form) and COX-2 (an
inducible form).

COX-1 is constitutively expressed and required to maintain

homeostasis. COX-2 is inducible and is over-expressed during numerous pathological
conditions, such as cancer and (24,86). A large number of growth factors, cytokines,
hormones and tumor promoters have been shown to induce COX-2. COX-2 is overexpressed in several cancers such as colorectal, gastric, breast, pancreatic, lung, and skin
cancer (19,20,24,86-90). High levels of COX-1 have been reported in the ER-dependent
well differentiated MCF-7 breast cancer cell line while ER-independent, invasive MDAMB-231 cells showed a low expression of COX-1 but a high level of COX-2 (91,92).
These findings suggest that COX-2 contributes to the growth and proliferation of ER (-)
breast cancer cells that and COX-2 inhibitors may be used to control breast
tumorigenesis. Another study demonstrated the over-expression of COX-2 protein in
transformed mammary epithelial cells (89).
Parret et al demonstrated for the first time that COX-2 was over-expressed in
primary breast cancers, not in the normal breast tissue (93). Showing that ER (-) breast
cancers are highly invasive and metastatic, Liu et al suggested that the high level of both
COX-2 protein and PGs found in the metastatic ER (-) breast tumors (MDA-MB-231)
13

might be responsible for cancer metastasis, and selective COX-2 inhibitors might be
useful treatment options for this kind of breast tumors (91).

This is in contrast to the

very low level of COX-2 protein found in the ER (+) breast cancer cell line (MCF-7).
Another study demonstrated the over-expresion of COX-2 protein in transformed
mammary epithelial cells (89).
The cyclic-AMP response element (CRE) and nuclear factor kappa-B (NFκB)
consensus sites on the COX-2 promoter are important for the expression of the COX-2
gene, because CRE acts as a positive regulatory element for COX-2 transcription (191).
NFκB regulates COX-2 expression in several cells and the inhibition of NFκB results in
the reduced expression of COX-2 and tumor cell proliferation in gastric cancer cells (26).
In rat mammary tumors NFκB is abnormally activated and the inhibition of constitutive
NFκB caused apoptosis (94).

Previous studies have shown the importance of CRE in

regulating COX-2 expression in epithelial cells.

CRE mediates the effect of src on

COX-2 expression in fibroblasts (95). In endotoxin-treated macrophages, the induction
of a murine COX-2 reporter gene by lipopolysaccaride (LPS) needed a CRE site and a
nuclear factor–interleukin-6 (NF-IL-6) (96).

Because the promoter region of the COX-2

gene has CRE, the activation of c-AMP by β2-adrenergic receptor (β2-AR) agonists will
likely induce the expression of the COX-2 gene whereas β2-AR antagonists will reduce
or inhibit the expression of the COX-2 gene (97). A highly specific β2-AR agonist,
zinterol, triggered AA release via the activation of the c-PLA2 in ventricular
cardiomyocytes and these responses to β2-AR induction were mediated by AA under cAMP control (98). Inoue et al. (99) demonstrated that CRE is necessary for effective
transcription of the human COX-2 gene since the deletion of this regulatory site on the
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COX-2 promoter decreased the promoter activity of COX-2 gene by 80 %.

This

suggests that modulators of the c-AMP-PKA pathway are important in the regulation of
the COX-2 gene.

On the other hand, the deletion of the NFκB regulatory site reduced

the promoter activity of the COX-2 gene only by 30 % (99). In mouse osteoblastic cells
c-AMP induced COX-2 expression (100), suggesting that the expression of COX-2
protein might be modulated by c-AMP either directly through PGE2, one of the end
products of COX-2-mediated AA metabolism, or indirectly through the PKA pathway
(88,101).
Beta-adrenergic receptors (β2-AR) are members of the superfamily of GTPbinding protein (G protein)-coupled receptors (GPCRs; Figure: 4).

GPCRs, which do

not have intrinsic catalytic activity, consist of an extracellular N-terminal domain; seven
membrane-spanning domains connected by three extracellular and three intracellular
loops; and an intracellular C-terminal cytoplasmic tail (102-104). These transmembrane
receptors regulate a host of diverse physiological processes and cellular functions,
including cardiovascular function, cellular metabolism, neurotransmission, secretion,
cellular growth and differentiation, ion channel activity, immune responses and
proliferation of certain tumor cells (105-107).

Upon binding of a ligand to GPCRs, the

bound GDP exchanges for GTP on the G-proteins, leading to the dissociation of Gprotein into active Gα-GTP and Gβγ subunits (Figure: 4).
Three different types of beta-adrenergic receptors (β1, β2, β3) have been identified
(105-108). Of these, β1- and β2-receptors are expressed in breast epithelia while β3receptors are expressed in adipose tissue. While all three beta-adrenergic receptors may
activate adenylyl cyclase/cAMP (Figure 5,6), the β2-receptor may additionally activate
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Figure 4: Mechanism of action of G proteins and GPCR. When an agonist binds to
GPCRs, the bound GDP exchanges for GTP on the G-proteins, leading to the dissociation
of G-protein into active Gα-GTP and Gβγ subunits. Once the agonist leaves the receptor,
the subunits associate each other again to form inactive GDP bound state.
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β-Adrenergic Receptor
Adenylyl Cyclase
cAMP

Protein Kinase A
Phospholipase
A2

Rap1
Transcription Factors
(CREB, CREM, ATF-1, NF-kB)

B-Raf

AA Release

Mek
ERK1/2
Transcription Factors
Figure 5: cAMP-dependent signal transduction in response to β-adrenergic receptor
stimulation. Binding of agonists to the receptor activates the enzyme adenylyl cyclase,
resulting in activation of the second messenger c-AMP and its associated kinase protein
kinase A (PKA). In turn, PKA may phosphorylate the transcription factors CREB,
CREM, ATF-1, or NF-kB or the MAPK cascade via activation of Rap-1 and b-Raf or it
may cause the release of AA via activation of phospholipase A2.
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β2-Adrenergic Receptor

c-src
STAT-3

Tyrk

P-Tyrk

Ras
Raf

PLA2 Activation

MEK

Release of AA

ERK1/2

AA-Metabolites

Transcription Factors
Figure 6. Beta2-adrenergic signal transduction via c-src. Pending on the cell type, binding
of agonists to β2-adrenergic receptors may recruit and activate c-src. Activation of c-src
may result in induction of the mitogen-activated protein kinase (MAPK) pathway via ras
to cytoplasmic serine/threonine kinases Raf, Mek, ERK and RSK, leading to induction of
transcription factors such as AP-1 and c-myc (101, 116). Additionally, ras may cause the
release of AA via activation of phospholipase A. Alternatively, induction of c-src
activity may results in tyrosine -phosphorylation and activation of Stat 3 (signal
transducer and activator of transcription 3).Tyrosine phosphorylation of STAT 3
facilitates its dimerization and translocation to the nucleus, leading to the transcription of
its target genes.
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the c-src/Stat-3 pathway (Figure 6) or potassium channels (109-115). Activation of PKA
as well as c-src can induce the release of AA via activation of phospholipase A2
(22,41,72,76) proliferation stimulated by NNK (15).

Moreover, the AA release induced

by NNK was completely inhibited by the β1-AR antagonist atenolol and β2-AR
antagonist ICI 118,551 (15).

This data suggests that the potential up-regulation of β-

ARs together with AA release may be the sole contributing factor for the lung
tumorigenesis and β-AR-AA-dependent regulatory pathways might be considered as a
crucial target for cancer prevention studies.
Similar to other G protein-coupled receptors, β-adrenergic receptors may also
activate G-protein-activated K+1 Channels (GIRK or Kir3) by binding to a membranebound effector complex, which includes
effector channel.

and β subunits of G proteins in addition to the

The α and β subunits possess some effector specificity and activate

the channel directly (117-120). Activation of heterotrimeric G-proteins by their coupled
receptor leads to dissociation of the G protein α and βγ subunits. Direct interactions of
G or Gβγ with effector proteins transduce the external signal into an intracellular
response (Figure: 4).
The G-protein-activated K+1 channels (GIRK or Kir3) are one of six groups
comprising the family of inward rectifying K+1 channels.

As indicated by their name,

GIRKs are activated by G proteins, most of which modulate many ion channels through
second messenger cascades (Figure 7).

GIRKs are activated via direct interaction of

the channel with Gβγ subunits released from β-adrenergic receptors and Gβγ subunits
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Figure 7: GIRK channel activation. GIRKs are activated by G proteins most of which
modulate many ion channels through second messenger cascades.
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induce both native and recombinant GIRK channels by binding directly to the N- and Cterminal regions of GIRK1. Intracellular Na+ and Mg+2 ions also activate these channels.
(117-120).
In Xenopus oocytes, where the GIRK1, G

S

and β2-AR were co-expressed,

isoproterenol activated GIRK1 channel activation and coupling between GIRK1 and β2AR, which was independent from the PKA pathway, but through the release of G protein
βγ subunits, suggesting that Gβγ subunits released from β-ARs activate the basal GIRK
current (118).

However, β2-AR activation by isoproterenol elevated the acetylcholine-

induced GIRK current through β2-AR, G

S

and PKA- mediated phosphorylation in atrial

cardiomyocytes, indicating that PKA phosphorylation of β2-AR might permit GIRK
channels to open either by direct phosphorylation of GIRK or activation of the auxiliary
modulators interacting with the GIRK channel (121). The stimulatory effect of PKA
phosphorylation on the GIRK might partly be explained by a PKA phosphorylation
consensus site found in the carboxy end of GIRK1 (119). The exact physiological role of
this site, which may be responsible for activation of several GIRK channels by growth
factors or kinases, remains to be elicited in the future.
Various effects of AA products called as eicosanoids and fatty acids have been
demonstrated on GIRK channels (82,122-129).

Induction of the endothelin receptor

inhibited GIRK channels via an AA and PLA2 mediated mechanism in Xenopus leavis
oocytes (122).

Several free fatty acids including AA, oleic and linoleic acid inhibited

ATP-dependent gating of G-protein –gated K+1 channels and GIRK1/4 recombinant
channels in oocytes (123).

AA and eicosanoids have direct effects on the GIRK
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channels by modification of the channel structure (125). It seems that the mechanism by
which free fatty acids are modulating many ion channels including GIRK may partly be
explained by high concentrations of total free fatty acids near the inner surface of the
membrane near the channels, as free fatty acids diffuse through cell membranes partly in
the unbound form (129).
Recently, over-expression of GIRK1 has been reported in a large proportion of
malignant breast cancers, particularly ER (-) cancers.

Because GIRK is involved in

signal transduction initiated by β2-adrenergic receptors in some cell types (130), its overexpression in breast cancer tissues suggests a potential role in beta-adrenergic growth
regulation of breast cancer cells.
In summary, several pieces of evidence suggest that beta-adrenergic receptors, cAMP, GIRK channels, and the AA-cascade may all work in concert to regulate the
growth of breast cancer cells and that components of these pathways are selectively
stimulated by several of the key risk factors that have been identified for the disease.

Hypothesis:
The central hypothesis of this research dissertation is that beta-adrenergic
receptors stimulate the growth of human breast cancer cell lines via activation of the
arachidonic cascade and GIRK channels. If this hypothesis is true, beta-blockers will
inhibit cell proliferation, MAPK and GIRK expressions, whereas beta-agonists will
induce cell proliferation through beta- adrenergic receptors. COX-1/2 and 5-LOX
inhibitors will block cell proliferation through the arachidonic acid cascade while
potassium channel blockers will inhibit cell proliferation via GRK channels.
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Specific aim:
Determine the effects of different concentrations of beta-blockers, beta-agonists,
inhibitors of COX-2, 5-LOX, and potassium channels on cell proliferation, MAPK and
GIRK expressions in a panel of ER (+) and ER (-) human breast cancer cell lines.
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CHAPTER 2: MATERIALS AND METHODS
Cells:
ER (+) human breast cancer cell lines MCF-7, ZR-75-1, MDA-MB-361, and ER
(-) human breast cancer cell lines MDA-MB-453, MDA-MB-435, MDA-MB-231, MDAMB-468 were obtained from the American Type Culture Collection.

All cells were

grown to 70-80% confluency in 75 cm2 vented cell culture flasks before experimental
procedures.

All cells were maintained in RPMI 1640 media with 10 % FBS

supplemented with L-glutamine (2mM (210 mg)) (Life Tech.) and penicillin (100U/ml) /
streptomycin (100 µg/ml) (Life Tech.) in an atmosphere of 5 % CO2 at 37°C.
Chemicals:
The site-selective antagonists for β1-and β2-adrenergic receptors atenolol and ICI
118,551 were purchased from Tocris.

The broad-spectrum β-adrenergic antagonist

propranolol and the COX inhibitor aspirin were purchased from Sigma.
adrenergic agonist isoproterenol was purchased from RBI.

The β-

The five lipoxygenase

activating protein (FLAP) inhibitor MK-886 was purchased from Biomol Research Lab.,
PA.

The non-specific LOX inhibitor NDGA, COX-2 inhibitor meloxicam and K-

channel inhibitor quinidine were purchased from Calbiochem. Tritiated thymidine was
purchased from Amersham.
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[3H] –Thymidine Incorporation Assay:
DNA synthesis was assessed with all cell lines using a standard tritiated
thymidine incorporation procedure in 96 well plates with a final volume of 200 µl/well
with a tritiated thymidine concentration of 0.5 µl / well (specific activity: 0.5 µCi /
200ml).

Initially, cells grown to 80% confluency were trypsinized and 15 000 cells

were plated into 96 well plates with DMEM medium including 10% FBS, 210 mg Lglutamine, 500 units penicillin, and 500 µg streptomycin was used for the inhibition
studies and low serum (0.1 % FBS) DMEM medium was used for the stimulation studies.
Cells were put into the incubator for 4 hours prior to the treatments. Cells were treated
with increasing concentrations of propranolol, atenolol, ICI 118,551, isoprotorenol
(50nM, 100nM, 250nM, 500nM, 750nM and 1µM), MK-886 (100nM, 1µM and 10µM),
aspirin (1µM, 10µM and 100µM), NDGA (100nM, 500nM, 1µM, 5µM, 10µM, 20µM,
30µM, 40µM), meloxicam (1µM, 10µM, 20µM, 30µM, 40µM, 60µM, 80µM, 100µM,
150µM, 200µM), and quinidine (10µM, 20µM, 40µM, 60 µM, 80µM, 100µM, 120µM)
for 24 hours at 37C0.

Cells, then, were lysed by using 0.1N NaOH and incorporated

[3H]-thymidine was separated from non-incorporated thymidine by vacuum filtration
using a microplate harvester (Micromate 196, Packard) of the lysed cells onto a backed
glass fiber filter.
isopropanol.

DNA was adhered onto filter by a final flush with 200µl/well of

The filters on which DNA adhered were cut by the harvester apparatus

into circular discs corresponding to each well of 96 well plates.

Each disc was placed

into a glass liquid scintillation vial including 3 ml of counting cocktail (Bio-Safe II,
Mount Prospect, IL).

Radioactivity bound to the filters was determined by liquid

scintillation counting.
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Relative-RT-PCR:
ER (-) MDA-MB-453 breast cancer cells were placed in DMEM media including
10 % FBS in the incubator 1 hour prior to the experiment. Cells were treated with 1µM
propranolol continuously for 1 week or 30 min every day for 1 week while maintained in
5 % CO2. Cells were trypsinized, and RNA was isolated by Trizol reagent (InvitrogenLife Technologies, Grand Island, NY). Cells were further purified to remove DNA with
an Absolutely RNA kit (Stratagene, La Jolla, CA). For the RT reaction, 2 µg DNase I
(Life Technologies) treated RNA, 1 µg random decamer primers (Ambion, Austin, TX)
and nuclease free water were heated to 70o C for 3 min., then placed on ice. To this was
added 0.5 mM each dNTP, 10 mM DTT, 30 U Prime RNase inhibitor (Eppendorf,
Westbury, NY), 200 U Moloney murine leukemia virus (M-MLV) reverse transcriptase
(Life Technologies), PCR buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2)
and nuclease free water in a final volume of 20 µl.

This was incubated at 37o C for 1

hour, and then the enzymes were heat inactivated for 10 min. at 92o C. A negative
control reaction was also performed without the M-MLV to determine if there was
genomic DNA contamination. PCR was done with 5 µl of the RT reactions.
mixed with 0.2 mM dNTPs,, PCR buffer

This was

1.25 U Ampli-Taq polymerase (Applied

Biosystems, Foster City, CA), DMSO, primers for GIRK-1 (500 nM), 5 µCi [α- 32P]dCTP (3000 Ci/mmole, Dupont-NEN, Boston, MA) and nuclease free water in a final
volume of 50 µl. The GIRK-1 primers are forward 5´-ctatggctaccgatacatcacag-3´ and
reverse 5´-ctgttcagtttgcatgcttcgc-3´, which span exon 1 and 2 (Schoots et al., 1997) and
amplifies a 441 bp fragment (bases 631-1072, Genbank Acession # 00239).
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Sequencing:
The PCR product was sequenced to verify the integrity of the PCR process.
Sequencing was done with the ABI Terminator Cycle Sequencing reaction kit on an ABI
373 DNA sequencer (Perkin-Elmer, Foster City, CA). Sequences were entered into
DNASIS software (Hitachi, S. San Francisco, CA). The sequence was homologous with
the published sequence (131).
A preliminary experiment was done with cDNA made from MDA-MB453 cells to
determine a cycle number of PCR amplification that is within the linear range, which is
critical for meaningful results to compare expression levels between samples. Reactions
were run on a MJ Research PTC-200 thermal cycler with the following conditions: 1
cycle of 2 min. at 94o C, then samples were taken at each odd number cycle from 15-35
cycles of 94o C, 30 sec; 55o C, 30 sec; 72o C, 45 sec.

A 10 µl sample of each PCR

reaction was heated at 95o C for 3 min., then loaded into a 5% TBE-urea Ready Gel (BioRad, Hercules, CA).

This underwent electrophoresis at 200 V in TBE buffer until the

xylene cyanol dye front reached the bottom of the gel. The gel was transferred to filter
paper, dried and exposed to film or imaged on a Molecular Dynamics 445 SI
phosphoimager (Sunnyvale, CA).

For this polyacrylamide gel, the 100 bp DNA ladder

was exchange labeled with T4 polynucleotide kinase and 30 µCi [γ-32P] ATP (3000
Ci/mM, Dupont-NEN). A 100,000 CPM aliquot of the DNA ladder was run on the gel.
It was determined that 31 cycles of PCR amplification was in the linear range of
amplification for cDNA from hamster cells.

A second preliminary experiment was done

with hamster cDNA. In this experiment 400 nM concentration of either 1:20, 1:15, 1:12,
1:9, 2:8 or 3:7 mixture of 18S primers/ 18S competimers (Ambion-Classic II) was added
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to the above PCR mixture and the samples underwent PCR amplification for 25 cycles.
The 18S ribosomal RNA primers/competimers are used as an invariant internal control
which allows correction for sample variation. Electrophoresis of the PCR products was
performed as described above.

It was determined that a 1:9 18S primer/competimers

ratio yielded a band similar in density to the gene-specific band and therefore was the
proper concentration to use when mRNA expression levels of the MDA-MB453 cells
were compared.
Western Blot:
For cell stimulation studies, cells were placed into low serum DMEM media (%
0.01 FBS) including 210 mg L-glutamine, 500 units penicillin, and 500 µg streptomycin
for 12-24 hours and maintained in 5 % CO2. Cells were washed with PBS and incubated
for additional 30 min in low serum media in 5 %CO2 prior to the experiment. Fresh 1
µM isoproterenol was added to the treatment group for 6 and 24 hours.

For inhibition

studies cell were placed in high serum DMEM media (10 % FBS) and maintained in 5 %
CO2 for 1 hour prior to the experiment.

Freshly made 1 µM propranolol, atenolol and

ICI 118,551 were added to the treatment groups for short and long intervals (15, 60 and
150 minutes), while 30 µM NDGA, and 100 µM meloxicam were added to the treatment
groups for 24 hours.

Cells were collected by removing DMEM media containing

designated treatment, wash with ice-cold PBS, and adherent cells were removed of with
0.25 % trypsin.

Cells were washed twice with PBS and centrifuged at 1000 rpms (60

g’s) to form a cell pellet.

The pellets either were placed at –800 C or lysed for the

subsequent procedures. Cells were lysed in 600 µl RIPA solution (1 x PBS, 1% NP40,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) including protease inhibitors:
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10 µl/ml phenylmethylsulphonyl fluoride (PMSF-10 mg/ml), 10 µl/mg sodium
orthovanadate (Na3VO4-100mM), and 30 µl/ml aprotinin (1.9mg/ml).

The cell lysate

was passed three or four times through a 21 gauge needle with subsequent addition of 10
µl PMSF (10mg/ml) followed by a 30 minute incubation on ice. The cell lysates were
centrifuged at 14000 rpms (1600 g’s) for 20 minutes at 40 C to separate supernate and
pellet. The supernate was collected to be used for subsequent assays.

The protein in

the supernate was concentrated by using CentriconTM 10 concentration columns
(Milipore) and centrifuged at 6000 rpms (4350 g’s) for 1 hour.

The protein

concentration was determined by using BCATM protein concentration assay. The 10 µl
protein sample and 200 µl bicinchronic acid (BCATM) reagent were placed into 96 well
microplate wells and incubated for 30 minutes at 370 C.

The protein samples were

quantified to obtain absorbance values in an EL 312 microplate reader (Bio-Tek
Instruments) at 550 nm wavelength. These absorbance values were converted to µg/ml
by using Prism 2.01 (GraphPad Inc.) regression analysis to calculate the necessary
amount of protein to load.
Protein (20 µg) for each sample was boiled in 2x SDS loading buffer (4% SDS,
0.1 M Tris-Cl at pH 6.8, 0.2% bromophenol blue, 20% glycerol) for 4 minutes at 950 C
and samples were immediately loaded onto a 10% Tris-HCl PAGE gel (Biorad) placed in
the electrophoresis apparatus (Biorad). The gel was allowed to run at 200 volts for 3045 minutes.
and

The gel including proteins was removed from the electrophoresis apparatus

was carefully placed in the transfer apparatus (Biorad).

The gel was

electrophoretically transferred to a nitrocelluse membrane (Midwest) in transfer buffer
(5.8 g Tris-hydroxymethyl-aminomethane, 2.9 g glycine, 3.7 ml 10% SDS, 200 ml
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ethanol, 800 ml deionized water) and run at 100 volts for 1 hour.

The membranes were

carefully removed from the apparatus and washed three times in wash solution (TBS
including 0.05% tween-20).

The membranes were blocked in blocking solution (5%

nonfat dry milk in TBS/0.05% tween-20) for 1 hour at room temperature, followed by
three 5 minute washes in wash solution.

Following blocking and washing, the

membranes were incubated for 1 hour, at room temperature, in blocking solution
containing rabbit polyclonal IgG for ERK 1/2 (200 µg/ ml) (Santa Cruz Biolabs) at a
dilution of 1:2000.

The membranes were washed three times for 5 minutes each and

incubated in blocking solution (5 % nonfat dry milk TBS/0.05% tween-20) including
anti-rabbit IgG-horse radish peroxidase linked secondary antibody (400 µg/ml) (Santa
Cruz Biolabs) at a dilution of 1:1000 for 1 hour at room temperature.

Positive

immunoreactivity was detected with the aid of western blot Luminol reagent (Santa
Cruz). The time for exposures varied.
For phosphorylated ERK 1/2 antibodies (phosph-p44/42 MAPK), the membranes
were blocked in a blocking buffer including 5% nonfat dry milk in TBS/0.1% tween-20
for 1 hour at room temperature.

Following three separate 5 minute washes in TBS/0.1%

tween-20, the membranes were probed with the primary polyclonal rabbit antibodies
specific for phosphorylated ERK 1/2 (New England Biolabs ) at the 1:1000 dilution in the
primary antibody dilution buffer (5% bovine serum albumin in TBS/0.1% tween-20), and
incubated overnight at 4o C with gentle agitation.

The phosphorylated ERK 1/2

antibody recognizes the phosphorylated tyrosine and threonine residues at positions 204
and 202, respectively.

The membranes, then, were incubated with horse radish

peroxidase conjugated anti-rabbit secondary antibody (Cell Signaling) at a dilution of 1:
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2000 in the blocking buffer for 1 hour at room temperature.

The protein bands were

detected by using LumiGLOTM chemiluminescent detection reagent (New England
Biolabs).
To ensure equal loading of protein samples, membranes were probed with
polyclonal rabbit IgG actin antibody (Sigma) at a 1:100 dilution using the same protocol
as for pERK 1/2. The secondary antibody against the actin IgG was an anti-rabbit IgG
coupled to horse radish peroxidase (Cell signaling) at the 1:10,000 dilution.
The membranes were stripped to remove the previously attached antibodies in the
stripping buffer (8 ml SDS [2%], 3.125 ml Tris-Cl pH 6.7 [62.5 mM], 350 µl βmercaptoethanol [100 mM], 38.5 ml deionized water) for 30 minutes to 1 hour in a water
bath at 50o C with gentle agitation.

The membranes were washed three times in

TBS/0.05% tween-20 for 5 minutes each and were stored in cellophane wrap at 4o C.

Densitometric analysis of protein bands:
Densitometric analysis of the autoradiograms was carried out by using UniScanTM
gel analysis software. The pixel numbers for every significant changes were determined
and placed on the legend of the figures.

Statistical analysis:
Statistical analysis was carried out by using Prism (Graph Pad Software; San
Diego, CA). One-way analysis of variance (ANOVA) followed by a Tukey-Kramer
multiple comparisons post test was utilized to compare the control groups with the
treatment groups. Differences were considered significant if p < 0.05.
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CHAPTER 3: RESULTS
Effects of the beta 1/2 –AR agonist isoprotorenol on human breast cancer cell lines:
Cell proliferation was measured by DNA synthesis as a function of triated
thymidine incorporation in all the cell lines studied. The results are demonstrated in
figures as bar graphs exhibiting counts per minute (cpm) at different concentrations. The
cpm values are exhibited as percentage change in the DNA synthesis for every cell line.
Thymidine incorporation studies showed that the β-agonist isoproterenol at
concentrations from 100 nM to 1 µM significantly increased DNA synthesis in the ER
negative breast cancer cell line, MDA-MB-453 (p<0.01) and the increase in the DNA
synthesis was almost doubled at the 1 µM concentration (p<0.01).

By contrast,

isoproterenol did not cause any change at these concentrations in any of the ER (+) breast
cancer cell lines, MCF-7, ZR-75-1, and MDA-MB-361 (Figure: 8 (a) and (d)).
Isoproterenol only at concentrations from 50 to 250 nM caused a significant DNA
synthesis increase in another ER (-) breast cancer cell line, MDA-MB-231 (p <0.05)
(Figure: 8 (b)). The increase in this cell line was less pronounced than in the other ER () cell line, MDA-MB-453.

In addition, isoproterenol significantly increased DNA

synthesis in the ER (-) MDA-MB-435 breast cancer cell line at concentrations from 50
nM to 1 µM (p <0.05) (Figure: 8 (c)). The increases in DNA synthesis were almost
identical at every concentration.

The only ER (-) breast cancer cell line that did not

respond to isoproterenol was MDA-MB-468 (Figure: 8 (b) and 1 (c)). Overall, cell
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Figure 8: Effects of the general beta 1/2-AR agonist isoproterenol on DNA synthesis.
Bars represent the mean and ± SD of each treatment group. Isoproterenol significantly
increased DNA synthesis in ER negative breast cancer cell lines, MDA-MB-453 (a), and
MDA-MB-231 (b). Isoproterenol did not cause significant increases in DNA synthesis in
both ER positive breast cancer cell line MCF –7 and in the ER negative breast cancer cell
line MDA-MB-468.
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Figure 8: (continued) Effects of the general beta 1/2-AR agonist isoproterenol on DNA
synthesis. Bars represent the mean and ± SD of each treatment group. Isoproterenol
significantly increased DNA synthesis in ER negative breast cancer cell line, MDA-MB435 (c). Isoproterenol did not cause significant increases in DNA synthesis in ER positive
breast cancer cell lines, MDA-MB-361 and ZR-75-1 (d).
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proliferation assay showed that all ER (-) breast cancer cell lines with the exception of
one were stimulated in a concentration-dependent manner by isoproterenol.
MAPK activation assays revealed that isoproterenol at the 1 µM concentration
caused a slight increase in the activation of ERK 1/2 in the ER (+) cell line MCF-7 at 6
hour, but it declined after 24 hours (Figure: 9). In the ER (-) cell line MDA-MB-453, on
the other hand, isoproterenol at the 1 µM concentration slightly increased activation of
ERK 1/2 after 24 hour (Figure: 9).

Effects of broad-spectrum β-adrenergic antagonist propranolol on human breast
cancer cell lines:
Propranolol decreased DNA synthesis at concentrations from 50 nM to 1 µM in
both ER (+) and ER (-) breast cancer cell lines studied.

Among the ER (+) breast cancer

cell lines, MCF-7 was mostly affected by propranolol with a significant decrease in DNA
synthesis at concentrations from 50 nM to 1 µM (p <0.01) (Figure: 10 (a)). Figure: 10 (a)
shows that there was a concentration-dependent in DNA synthesis with an almost
complete inhibition at the 1 µM concentration.

Two other ER (+) breast cancer cell

lines, MDA-MB-361 and ZR-75-1 also responded to propranolol with a significant
decrease in DNA synthesis (p < 0.01) (Figure: 10 (b)).

The inhibition of DNA

synthesis was concentration-dependent in ZR-75-1 cells, while its effects reversed in
MDA-MB-361 cells at the 1 µM concentration.
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Figure 9: Effect of 1 µM isoproterenol on pERK1/2 (p44/ p42) activation in MCF-7 and
MDA-MB-453 cell line. Isoproterenol caused a slight increase in the activation of ERK
1/2 in the ER (+) cell line MCF-7 at 6 hour, but it declined after 24 hours. In the ER (-)
cell line MDA-MB-453, on the other hand, isoproterenol at the 1 µM concentration
slightly increased activation of ERK 1/2 after 24 hour. (Note that parentheses represent
densitometry values)
1: MCF-7
2: MCF-7
3- MCF-7
4: MCF-7

6 h- Control (105)
6 h- Isoproterenol (135)
24 h- Control (132)
24 h- Isoproterenol (95)

5: MDA-MB-453
6: MDA-MB-453
7: MDA-MB-453
8: MDA-MB-453
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Figure 10: Effect of the broad-spectrum beta-blocker propranolol on DNA synthesis. Bars
represent the mean and ± SD of each treatment group. Propranolol significantly
decreased DNA synthesis both in ER negative breast cancer cell line, MDA-MB-453 (a),
and ER positive breast cancer cell lines, MDA-MB-361 (b), MCF-7 (a) and ZR-75-1 (b).
The decrease in MCF-7 cells was more pronounced than in the other cell lines.
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Figure 10: (continued) Effect of the broad-spectrum beta-blocker propranolol on DNA
synthesis. Bars represent the mean and ± SD of each treatment group. Propranolol
significantly decreased DNA synthesis in ER negative breast cancer cell lines, MDAMB-468, MDA-MB-231 (c) and MDA-MB-435 (d). The decrease in MDA-MB-231 cell
line was more pronounced than in the other cell lines.
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Among the ER (-) breast cancer cell lines, DNA synthesis was most significantly
reduced in MDA-MB-453 and MDA-MB-231 cell lines (p < 0.01) (Figure: 10 (a) and
(c)). There was an almost 70 % decrease in DNA synthesis in MDA-MB-453 cells and a
50 % inhibition in MDA-MB-231cells at the 1 µM concentration. In the remaining ER (-)
breast cancer cell lines MDA-MB-435 and MDA-MB-468 inhibitions of DNA synthesis
were about 35 % at the 750 nM concentration and 25 % at the 1 µM concentration (p <
0.05) (Figure: 10 (c) and (d)). Overall, cell proliferation assays demonstrated that the ER
(+) breast cancer cell lines were significantly more responsive to inhibitory effects of
propranolol.
MAPK expression assays showed that propranolol at the 1 µM concentration
reduced the expression of ERK 1/2 in the ER (+) cell line MCF-7 at only 150 minute
(Figure: 11). In the ER (-) cell line MDA-MB-453 propranolol (1 µM) reduced the
expression of ERK 1/2 at 60 and 150 minutes (Figure: 11).

Propranolol did not cause

any changes in the activation of ERK 1/2 in both ER (+) and ER (-) breast cancer cell
lines, MCF-7 and MDA-MB-453, respectively (Figures: 12 and 13). Overall, these
results suggest that propranolol decreased total MAPK protein expression on the DNA
level without changing the phosphorylation status of MAPK.
In the RTPCR experiments, continuous exposure to 1 µM propranolol for 7 days
increased GIRK1 expression in the ER (-) breast cancer cell line, MDA-MB-453 (Figure:
14 (a)). However, when MDA-MB-453 cells were treated with 1 µM propranolol 30
minutes every day for 7 days, the GIRK1 expression did not change (Figure: 14 (b)).
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Figure 11: Effect of 1 µM propranolol on ERK 1/2 expression in two breast cancer cell
lines. Propranolol decreased the expression of ERK 1/2 in the ER (+) cell line MCF-7 at
only 150 minute (Pixel values: 90 / 75). In the ER (-) cell line MDA-MB-453 propranolol
decreased the expression of ERK 1/2 at 60 and 150 minutes. (Pixel values: 116 / 78 for
60 min; 116 / 43 for 150 min.)
A: MCF-7 –ER (+)
B: MDA-MB-453- ER (-)
1: 0 min 2: 0 min 3: 15 min 4: 15 min-

Control
Propranolol
Control
Propranolol

5: 60 min- -Control
6: 60 min- Propranolol
7: 150 min --Control
8: 150 min- Propranolol
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Figure 12: Effect of 1 µM propranolol on pERK1/2 (p44/ p42) activation in the ER (+)
MCF-7 cell line. There was no change in the activation status of ERK 1/2.
1: 0 min- Control
2: 0 min- Propranolol
3: 15 min - Control
4: 15 min- Propranolol

5: 60 min6: 60 min7: 150 min 8: 150 min-
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Control
Propranolol
Control
Propranolol

Figure 13: Effect of 1 µM propranolol on pERK1/2 (p44/p42) activation in the ER (-)
MDA-MB-453 cell line. There was no change in the activation status of ERK 1/2.
1: 0 min- Control
2: 0 min- Propranolol
3: 15 min - Control
4: 15 min- Propranolol

5: 60 min6: 60 min7: 150 min 8: 150 min-
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Control
Propranolol
Control
Propranolol

(a)

(b)

Figure 14: Effect of 1 µM propranolol on GIRK1 expression in ER (-) MDA-MB-453
breast cancer cells. GIRK1 was over-expressed when the cells were continuously exposed
to propranolol for 7 days (pixel values: 0.55 / 0.90) (a). GIRK1 expression did not
change when the cells were exposed to propranolol for 30min per day for 1 week (b).
1-5: Control
6-10: Propranolol
11-12: Negative Control
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These results suggest a possible link between GIRK1 channel activity and β-AR
signaling and indicate that up-regulation in channel expression in response to chronic
continuous exposure to propranolol was caused by the well-documented antagonistinduced up-regulation of β-adrenergic receptors.
Effects of the selective β1-AR antagonist atenolol on human breast cancer cell lines:
The ER (+) cell line MCF-7 was the most responsive to atenolol treatment with a
50 % reduction of DNA synthesis below basal level (p<0.01) (Figure: 15 (a)). The
inhibition was concentration-dependent and reached a maximum at the 1 µM
concentration. The ER (+) breast cancer cell lines MDA-MB-361 and ZR-75-1 exhibited
almost no inhibition in response to atenolol with only about 20 % reduction of DNA
synthesis below controls at each concentration (Figure: 15 (b)).
ER (-) breast cancer cell lines, generally, were not much affected by increasing
concentrations of atenolol (Figures: 15 (a), (c) and (d)).

Only MDA-MB-468 cell s

exhibited a significant inhibition of DNA synthesis (about 45 % below controls; p <0.05;
Figure: 15 (c) and (d)).

On the other hand, DNA synthesis decreased by about 30 % in

MDA-MB-453 (Figure: 8 (a)) and MDA-MB-231 cells (Figure: 8 (c)), while it was about
20 % in MDA-MB-435 cells (Figure: 15 (d)).

Taken together, only MCF-7 [ER (+)]

and MDA-MB-468 [ER (-)] breast cancer cell lines demonstrated a significant response
to atenolol.
Atenolol at the 1 µM concentration did not cause any significant changes in the
expression of ERK 1/2 in either MCF-7 (Figure: 16 (a)) or MDA-MB-453 (Figure: 16
(b)) breast cancer cells.
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Figure 15: Effect of increasing concentrations of the selective β1-AR antagonist atenolol
on DNA synthesis. Bars represent the mean and ± SD of each treatment group. Atenolol
significantly decreased DNA synthesis in the ER positive breast cancer cell line, MCF-7
(a), and in the ER negative breast cancer cell line, MDA-MB-453 (a). MCF-7 cells line
were most responsive to atenolol treatment. Two ER positive cell lines exhibited no
significant response to atenolol (b).
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Figure 15: (continued). Effect of increasing concentrations of the selective β1-AR
antagonist atenolol on DNA synthesis. Bars represent the mean and ± SD of each
treatment group. Atenolol significantly decreased DNA synthesis in the ER negative
breast cancer cell line, MDA-MB-468 (c, d). Two other ER negative cell lines exhibited
no significant inhibition in response to atenolol (c, d).
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(a)

(b)

Figure 16: Effect of 1 µM atenolol on ERK1/2 expression in ER (+) MCF-7 (a) and ER
(-) MDA-MB-453 (b) cell lines. There was no change in the expression status of ERK
1/2.
1: 0 min- Control
2: 0 min- Atenolol
3: 15 min - Control
4: 15 min- Atenolol

5: 60 min- Control
6: 60 min- Atenolol
7: 150 min- Control
8: 150 min- Atenolol
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Effect of the selective β2-AR antagonist ICI 118,551 on human breast cancer cell
lines:
The ER (+) breast cancer cell lines with the exception of ZR-75-1 significantly
responded to increasing concentrations of the β2-AR antagonist ICI 118-551.

The

inhibition of DNA synthesis in MCF-7 cell line was about 45 % below that of controls
(p<0.05) (Figure: 17 (a)). The most dramatic response to ICI 118,551 was observed in
MDA-MB-361 cell with an 80 % decrease in the DNA synthesis at 500 nM, 75 % at 750
nM and 60 % at the 1 µM concentration (p< 0.01) (Figure: 17 (b)). In cell line ZR-75-1,
a significant 40 % inhibition in DNA synthesis was observed only at a 1 µM
concentration (p<0.05) (Figure: 17 (b)).
Similar to the MCF-7 cell line, the ER (-) breast cancer cell line MDA-MB-453
showed only a 45 % reduction in DNA synthesis (p < 0.05) (Figure: 17 (a)), whereas
MDA-MB-231 cells exhibited a concentration-dependent response with a 65 % inhibition
at 500 nM (p <0.01), 60 % at 750 nM (p < 0.01) and 30 % at 1 µM concentration (p <
0.05) (Figure: 17 (c)).

The other two ER (-) cell lines reacted in a similar manner. At

500 and 750 nM ICI 118, 551 concentrations, the reductions in DNA synthesis were
almost 40 % below control (p <0.05) even though the decrease reversed at the 1 µM
concentration being 35 % and 22 % for the MDA-MB-468 and MDA-MB-435,
respectively (Figure: 17 (c) and (d)). Overall, the response of the ER (+) cell line MDAMB-361 and the ER (-) cell line MDA-MB-23 to ICI 118, 551 was significantly more
pronounced than the response of other cell lines.
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Figure 17: Effect of increasing concentrations of selective β2-AR antagonist ICI 118,551
on DNA synthesis. Bars represent the mean and ± SD of each treatment group. ICI
118,551 significantly decreased DNA synthesis in ER positive breast cancer cell lines,
MCF-7 and MDA-MB-361 (b), and ER negative breast cancer cell line, MDA-MB-453
(a). MDA-MB-361 was the most responsive to atenolol treatment though in ZR-75-1
significant inhibition was seen only at 1 uM concentration.
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Figure 17: (continued) Effect of increasing concentrations of the selective β2-AR
antagonist ICI 118,551 on DNA synthesis. Bars represent the mean and ± SD of each
treatment group. ICI 118,551 significantly decreased DNA synthesis in ER negative
breast cancer cell lines, MDA-MB-231 (c), MDA-MB- 435 (d) and MDA-MB-468 (d).
The MDA-MB-231 cell line was much more affected by ICI 118, 551 treatments than
other cell The ER (+) MCF-7 cell line did not show any difference in the expression
status of lines.
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(a)

(b)

Figure 18: Effect of 1 µM ICI 118,551 on ERK1/2 expression in ER (+) MCF-7 (a) and
ER (-) MDA-MB-453 (b) cell lines. There was no change in the expression status of
ERK 1/2 in MCF-7 (a) whereas ICI 118,551 reduced the expression of ERK 1/2 at 60
and 150 minutes in MDA-MB-453 breast cancer cell line (pixel values: 277 / 126 for 60
min; 269 / 132 for 150 min.) (b).
1: 0 min2: 0 min3: 15 min 4: 15 min-

Control
ICI 118,551
Control
ICI 118,551

5: 60 minControl
6: 60 minICI 118,551
7: 150 min- Control
8: 150 min- ICI 118,551
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The ER (+) MCF-7 cell line did not show any difference in the expression status
of ERK 1/2 (Figure: 18 (a)) while only the ER (-) breast cancer cell line MDA-MB-453
demonstrated a declined ERK 1/2 expression at 60 and 150 minutes in response to 1 µM
ICI 118, 551 (Figure: 18 (b)).

Effects of the COX 1/2 inhibitor aspirin on human breast cancer cell lines:
The COX 1/2 inhibitor aspirin reduced DNA synthesis in the ER (+) cell line,
MCF-7 and in the ER (-) cell line MDA-MB-453 (Figure: 19 (a)). Both cell lines
responded to aspirin treatment in the same manner at the 1 µM concentration with DNA
synthesis being reduced almost 40 % below the controls (p < 0.05). However, the MDAMB-453 cell line continued to be inhibited by increasing concentrations of aspirin (P
<0.05), while MCF-7 started to lose its responsiveness to aspirin with inhibition of DNA
synthesis decreasing from 40 % to 30 % though it was still significant (p< 0.05). These
findings suggest that the ER (-) cell line MDA-MB-453 may have higher levels of
expression of COX 1/2 than the ER (+) cell line MCF-7.
Effect of the FLAP (5-LOX activating protein) inhibitor MK-886 on human breast
cancer cell lines:
The FLAP inhibitor MK-886 reduced DNA synthesis in ER (-) and ER (+) cell
lines (Figure: 19 (b)).

The decline in DNA synthesis at a concentration of 100 nM

concentration of MK-886 was almost identical for both cell lines, being 45 % and 50 %
below controls for MCF-7 and MDA-MB-453, respectively (p < 0.05).

Nonetheless,

when the concentrations of MK-886 were increased to 1 and 10 µM, the ER (-) breast
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Figure 19: Effects of increasing concentrations of aspirin and MK-886 on DNA
synthesis. Bars represent the mean and ± SD of each treatment group. Aspirin
significantly decreased DNA synthesis in MCF-7 and MDA-MB-453 (a). Inhibition was
more pronounced in MDA-MB-453 than MCF-7. At each concentration, MK-886
treatment resulted in a significant decrease as compared with controls (b). Both cell lines
were affected by MK-886. The ER negative cell line MDA-MB-453 was more responsive
to the inhibitory action of MK-886.
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cancer cell line MDA-MB-453 demonstrated a strong reduction in DNA synthesis ( 80 %
at the 1 µM and 95% at the 10 µM; p <0.01) whereas the ER (+) cell line MCF-7
exhibited somewhat less but concentration-dependent reduction in DNA synthesis at
these concentrations ( 68 % at the 1 µM and 70 % at the 10 µM concentration). Similar
to the results obtained with aspirin, these findings suggest that the ER (-) cell line MDAMB-453 may have higher levels of 5-LOX expression than the ER (+) cell line MCF-7.

Effect of the specific COX-2 inhibitor meloxicam on human breast cancer cell lines:
Generally, meloxicam up to 80 µM concentrations caused little decrease in DNA
synthesis in the breast cancer cell lines studied.

At a concentration of 80 µM,

meloxicam, reduced DNA synthesis by about 45 % below controls in the ER (+) cell line
ZR-75-1 (p <0.001) (Figure: 20 (a)), whereas the other three ER (-) cell lines responded
with only with a reduction in DNA synthesis of about 20 % (p >0.05), % 27 (p <0.05)
and 30 % (p<0.05) over time (Figure: 20 (a) and (b)). At a concentration of100 µM, the
most pronounced inhibition of DNA synthesis was observed in both ER (-) breast cancer
cell lines with MDA-MB-231 showing an about 67 % reduction over time (p <0.001)
while the ER (+) breast cancer cell line ZR-75-1 showed an almost 70 % inhibition (p
<0.001) (Figure: 20 (a)).
Of the other two ER (-) cell lines, only MDA-MB-468 cells showed a significant
inhibition in DNA synthesis 9about 35 % over time p <0.01) at this concentration
(Figure: 20 (b)). As it illustrated in figures 20 (a) and 20 (b), all ER (+) and ER (-) cell
lines responded with a significant inhibition of DNA synthesis to 150 and 200 µM
concentrations of meloxicam (p <0.001). In addition, the ER (+) ZR-75-1 and ER (-)
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Figure 20: Effect of increasing concentrations of meloxicam on DNA synthesis. Bars
represent the mean and ± SD of each treatment group. Meloxicam significantly decreased
DNA synthesis in all cell lines at higher concentrations. The ER (-) MDA-MB-231 (a)
and ER (+) ZR-75-1 cell lines appeared to be more sensitive to the effect of Meloxicam
than the other two ER (-) cell lines (b).
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MDA-MB-231 cell lines were more responsive to meloxicam treatment at these
concentrations than the other cell lines. Overall, these results suggest that at 100 and 150
µM concentrations the ability of meloxicam to inhibit DNA synthesis was very strong.
MAPK expression studies exhibited that (with the exception of the ER (+) breast
cancer cell line MCF-7 and the ER (-) cell line MDA-MB-231) there was no reduction in
ERK 1/2 expression in response to 100 µM meloxicam (Figure: 21 (a), (b) and (c)). The
expression of ERK 1/2 appeared slightly decreased in MCF-7 cells (Figure: 21 (c), lanes
3 and 4), while only ERK 1 expression was reduced in MDA-MB-231 cells (Figure: 21
(c), lanes 7 and 8) though the status of ERK 2 remained unchanged. The MDA-MB-453
cell line showed an increase in ERK 1/2 expression (Figure: 21 (a), lanes 7 and 8),
whereas the other three cell lines, MDA-MB-435, MDA-MB-468 and ZR-75-1 did not
exhibit any change in the expression status of ERK 1/2 (Figure: 21 (a) and (b)). These
results, suggest that only two ER (-) breast cancer cell lines, MDA-MB-231 and MDAMB-453, and one ER (+) breast cancer cell line MCF-7 responded with a modulation in
ERK 1/2 expression to meloxicam.

Effects of the non-specific 5-LOX inhibitor NDGA on human breast cancer cell
lines:
NDGA was used at lower concentrations than meloxicam. In the two ER (-) cell
lines, MDA-MB-435 and MDA-MB-468, a significant reduction in DNA synthesis
occurred at the higher concentrations (Figure: 22 (a)).

The three lowest concentrations

(100 nM, 500 nM , 1 µM) did not cause significant changes in DNA synthesis in any of
the cell lines studied. However, higher concentrations of NDGA reduced DNA synthesis
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(a)

Figure 21: Effect of 30 µM NDGA and 100uM meloxicam on ERK1/2 protein
expression in ER (+) ZR-75-1 and ER (-) MDA-MB-453 (a). The MDA-MB-453 cell line
showed an increase in ERK 1/2 protein expression (lanes 7 and 8) (pixel values: 90 /
146).
1: ZR-75-1 24 h- Control
2: ZR-75-1 24 h- NDGA
3- ZR-75-1 24 h- Control
4: ZR-75-1 24 h- Meloxicam

5: MDA-MB-453
24 h- Control
6: MDA-MB-453
24 h- NDGA
7: MDA-MB-453
24 h -Control
8: MDA-MB-453 24 h-Meloxicam
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(b)

Figure 21: (continued) Effect of 30 µM NDGA and 100uM Meloxicam on ERK1/2
expression in ER (-) MDA-MB-435 and ER (-) MDA-MB-468 cell lines (b).
1: MDA-MB-435
2: MDA-MB-435
3- MDA-MB-435
4: MDA-MB-435

24 h- Control
24 h- NDGA
24 h- Control
24 h- Meloxicam

5: MDA-MB-468
6: MDA-MB-468
7: MDA-MB-468
8: MDA-MB-468
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24 h- Control
24 h- NDGA
24 h -Control
24 h- Meloxicam

(c)

Figure 21: (continued) Effect of 30 µM NDGA and 100uM Meloxicam on ERK1/2
protein expression in ER (+) MCF-7 and ER (-) MDA-MB-231 cell lines. The expression
of ERK 1/2 protein appeared slightly decreased in MCF-7 cells (lanes 3 and 4), while
only ERK 1 protein expression was reduced in MDA-MB-231 cells (lanes 7 and 8),
though the status of ERK 2 expression remained unchanged in MDA-MB-231 cell line.
1: MCF-7 24 h- Control
2: MCF-7 24 h- NDGA
3- MCF-7 24 h- Control
4: MCF-7 24 h- Meloxicam

5: MDA-MB-231
24 h- Control
6: MDA-MB-231
24 h- NDGA
7: MDA-MB-231
24 h -Control
8: MDA-MB-231 24 h-Meloxicam.
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Figure 22: Effect of increasing concentrations of NDGA on DNA synthesis. Bars
represent the mean and ± SD of each treatment group. NDGA reduced DNA synthesis in
all cell lines. At higher concentrations, three ER (-) cell lines MDA-MB-435 (a), MDAMB-468 (a) and MDA-MB-231 (b) were more responsive to NDGA treatment than the
ER (+) cell line ZR-75-1 (b).
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significantly in these two ER (-) breast cancer cell lines. The reductions were 25 % at 5
µM (p <0.05), 38 % at 10 µM (p <0.001), 62 % at 20 µM (p <0.001), 95 % at 30 µM (p
<0.001) and 78 % at 40 µM (p <0.001) of NDGA in MDA-MB-468 breast cancer cells
(Figure: 22 (a)).

The other ER (-) cell line, MDA-MB-435, demonstrated a

concentration-dependent decrease in DNA synthesis from 50 to 97% below controls
(p<0.001) in response to concentrations of NDGA from 5 µM to 40 µM.
The lowest concentration of NDGA (100 nM) only reduced DNA synthesis
significantly (20%, p<0.05) in the ER (-) breast cancer cell line MDA-MB-231 (Figure:
22 (b)). The higher NDGA concentrations up to 40 µM caused significant reductions in
DNA synthesis from 25 % to 90 % over time in this cell line (p <0.001). NDGA
concentrations from 500 nM to 40 µM decreased DNA synthesis in the ER (+) breast
cancer cell line ZR-75-1 (p <0.001) (Figure: 22 (b)), whereas the lowest concentration
(100 nM) exhibited no significant inhibition in this cell line. Overall, these results
suggest that NDGA was more effective in inhibiting DNA synthesis at lower
concentrations, and all three ER (-) cell lines (MDA-MB-435, MDA-MB-468 and MDAMB-231) were more responsive to NDGA treatment than the ER (+) cell line ZR-75-1.
Reductions in ERK 1/2 expression in response to NDGA were only observed in
the three ER (-) breast cancer cell lines (MDA-MB-435, MDA-MB-468 and MDA-MB231 (Figure: 21 (a), (b) and (c)). NDGA at 30 µM decreased the expression of MAPK
(ERK 1/2) in both MDA-MB-435 (Figure: 21 (b), lanes 1 and 2), and MDA-MB-231
cells (Figure: 21 (c), lanes 5 and 6), while only ERK 1 expression was decreased in
MDA-MB-468 (Figure: 21 (b), lanes 5 and 6).
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In summary, NDGA only caused

significant inhibition of MAPK expression in ER (-) breast cancer cell lines.
Effects of the K+1 channel inhibitor quinidine on human breast cancer cell lines:
Quinidine significantly reduced DNA synthesis in both ER (+) MCF-7 and ER (-)
MDA-MB-453 breast cancer cell lines (Figure: 23).

The reduction was more

pronounced in MDA-MB-453 than MCF-7. DNA synthesis in MDA-MB-453 cells was
significantly decreased at each concentration of quinidine tested. In MCF-7 cells the
lowest concentration of quinidine (10 µM) did not inhibit DNA synthesis whereas all
higher concentrations caused significant inhibitions.

In both cell lines, the decline in

DNA synthesis was dependent-dependent (30 % at 10 µM (p <0.05), 60 % at 40 µM (p
<0.001) and 81 % at 120 µM (p <0.001) for MDA –MB-453; and 15 % at 10µM (p
>0.05), 48 % at 60 µM (p <0.001) and 70 % at 120 µM for the MCF-7 breast cancer cell
line.

These result suggests that quinidine was an effective inhibitor for both ER (+) and

ER (-) breast cancer cell lines and that ER (-) cell line much more sensitive to this effect.
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Figure 23: Effect of increasing concentrations of quinidine on DNA synthesis. Bars
represent the mean and ± SD of each treatment group. Quinidine significantly reduced
DNA synthesis in both ER (+) MCF-7 and ER (-) MDA-MB-453 breast cancer cell lines.
The inhibition in the DNA synthesis was more pronounced in MDA-MB-453 cell line
than MCF-7.
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CHAPTER 4: DISCUSSION
Breast cancer is the most common cancer in the world with at least one million
new cases each year and comprises 18 % of all female cancers (132). Even though
surgery is the major curative action to remove the primary cancerous lesion, frequent
relapses at different sites due to micrometastases is a serious problem that often kills the
patient.

Conventional cancer therapy often causes undesirable side effects because it is

not selective for all cancer cells.

Improvements in the understanding of the molecular

mechanisms of breast cancer development either genetically or epigenetically have led to
many new therapeutic developments that may inhibit invasive breast cancer progression.
The latest approaches for the prevention of breast cancer at the molecular level include
the administration of newly developed monoclonal antibodies against human epidermal
growth factor receptor-2 (HER-2) and receptor tyrosine kinases (RTKs), specific kinase
inhibitors, ER antagonists, cell cycle kinase inhibitors, histone deacetylase inhibitors to
suppress gene expressions, angiogenesis inhibitors, metalloproteinase inhibitors, new
cytotoxic agents and radiation called adjuvant therapy, selective estrogen receptor
modulators (raloxifene), apoptosis inducers, telomerase inhibitors, dietary modulators
and vitamins, NSAIDs and specific COX-2 inhibitors, and smart drugs targeting only
tumor cells and sparing the normal cells (133).
The growth of breast cancer cells is regulated by many factors, including steroid
hormones and peptide growth factors, which induce different intracellular signaling
pathways.

The growth factors bind to tyrosine kinase-associated transmembrane

receptors so that they can modulate the other signaling pathways to induce the expression
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of transcription factors, leading to the growth and proliferation of tumor cells. Estrogen
and several growth factors interact with each other, by co-operating through their
respective pathways in the regulation of the proliferation and progression of ER (+)
breast tumors (134), while in the ER (-) tumors, the growth factors, particularly EGF,
without estrogen induces the downstream signaling pathways when it binds to its receptor
(54,58,135-139).
The critical mitogen in many breast cancers is the steroid hormone estrogen even
though certain growth factors also play a crucial role in modulating mammary gland
development and breast cancer progression.

In addition to cell growth and proliferation

mediated by estrogen in breast carcinogenesis, mutations in critical genes are often
needed for cancer progression (42,134,140).

Increased ER expression in most breast

tumors is associated with a possible ER gene amplification, stabilization of the ER
transcript and increased efficiency of translation of ER protein.

The ER loss in the ER

(-) tumors is associated with factors effecting the efficient translation of the ER protein.
These factors may include ER gene mutation, generation of different ER variants,
aberrant hypermethylation of ER CpG island in the regulatory region of the ER gene,
inactivation of the co-activators or over-expression of co-repressor and the loss of
transcription factor ERF-1 that are required for enhanced ER gene expression (42, 141,
142).
Real time polymerase chain reaction (PCR) studies by Iwao et al. demonstrated
that in the ER (+) tumors, ERα mRNA levels were much higher while in the ER (-)
tumors, ERβ mRNA levels were higher (143). Furthermore, ERβ / ERα ratio was higher
in the ER (-) tumors than ER (+) tumors , suggesting that the quantitative analysis of ERα
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and β by the real time PCR corresponds to the analysis of these receptors by the
conventional RT-PCR. Similarly, it was also demonstrated by the real time PCR that the
ERα was over-expressed in the PR (+) tumors whereas the ERβ levels were higher in the
PR (-) tumors (143).
We conducted cell proliferation assays using the incorporation of [3H]-thymidine
to monitor DNA synthesis.

Our studies demonstrate that the broad-spectrum β-

adrenergic antagonist propranolol significantly reduced cell growth in all cell lines
studied, indicating growth regulation by β1-or β2-ARs in these cells.

The lowest

concentration of propranolol, 50 nM, caused significant decrease in DNA synthesis only
in the ER (+) cell lines, MCF-7 and MDA-MB-361, and in the ER (-) cell line MDAMB-231. The decrease in DNA synthesis was concentration-dependent in ER (+) cell
lines MCF-7 and ZR-75-1, and ER (-) cell line MDA-MB-453 at concentrations from 50
nM to 1 µM, suggesting that these cell lines may over-express β-AR. These finding
suggest that binding of propranolol to these receptors likely did not saturate up to the 1
µM concentration. However, other cell lines studied exhibited an increase in DNA
synthesis at 500 and 750 nM concentrations of propranolol, suggesting that propranolol
may have caused a β-AR up-regulation in these cell lines or that these cell expressed
excessive numbers of β-ARs.
Among the ER (+) cell lines, only MCF-7 responded to the β-1 specific antagonist
atenolol.

In this cell line, the inhibition in DNA synthesis was significant at

concentrations from 250 nM to 1 µM.

Lower concentrations were not effective. The

ability of atenolol to significantly inhibit DNA synthesis in only MCF-7 suggests that
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only this cell line may express β1-ARs.

The ER (-) cell line MDA-MB-468 was most

responsive to increasing concentrations of atenolol from 250 nM to 1 µM. MDA-MB453 cells were affected by atenolol treatment at both 750 nM and 1 µM concentrations
while MDA-MB-231 were affected by atenolol only at the 750 nM concentration.

The

ER (-) cell line MDA-MB-435 did not respond to atenolol treatment, suggesting an
absence of β1-ARs. MDA-MB-468 cells were significantly more responsive to atenolol,
suggesting the presence of up-regulated β1-ARs.
The selective β2-AR antagonist ICI 118,551 caused significant inhibitions in
DNA synthesis in all cell lines tested. Both ER (+) and ER (-) breast cancer cell lines
were affected by ICI 118,551 in a concentration-dependent manner, even though some of
them exhibited somewhat different inhibition status at different concentrations.

The

most responsive cell line was the ER (+) cell line MDA-MB-361 in which DNA
synthesis was inhibited even at the lowest concentration of ICI118,551 (50 nM).
µM, the response reversed, suggesting possible receptor desensitization.

At 1

The second

ER (+) cell line MCF-7, also demonstrated a concentration-dependent inhibition of DNA
synthesis by ICI 118,551 although to a lesser degree than MDA-MB-361 cells. Our
results, at this point, implicate that these two ER (+) cell lines may express β2-ARs.
Earlier results from our laboratory have also shown that these two cell lines significantly
responded to propranolol. The ER (+) cell line ZR-75-1 showed a significant reduction
in DNA synthesis only at the highest concentration of ICI 118,551 (1 µM), indicating
either the presence of constitutively over-expressed β2-ARs or a lack of this receptor.
However, the latter explanation seems unlikely in view of the significant response to
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propranolol.

Because we did not assess expression levels of β1/2-ARs in this project,

these interpretations are speculative at this time.
All ER (-) cell lines responded to ICI 118,551 treatments. MDA-MB-453 cells
showed an increasing decline in DNA synthesis with increasing concentrations of ICI
118,551.

The response of this cell line to all β-AR antagonists, including the broad-

spectrum β-AR antagonist propranolol, the β1-AR antagonist atenolol and the β2-AR
antagonist ICI, 118, 551 suggests the presence of both, β1-and β2-ARs. However, in the
other three ER (-) cell lines (MDA-MB-231, MDA-MB-435, and MDA-MB-468) DNA
synthesis was inhibited up to 750 nM of ICI 118,551 while the effect reversed at the 1
µM concentration. This may reflect a desensitized β2-AR in these cells even though at
this concentration the inhibitions were still significant.

Of particular interest was the

finding that MDA-MB-231 cells responded to ICI 118,551 treatment most dramatically at
each concentration up to 750 nM, indicating that this cell line may over-express β2-ARs.
Similarly, the ER (-) cell line MDA-MB-435 may also over-express or have only β2-ARs
because it responded significantly only to the broad-spectrum β-AR antagonist
propranolol and to the β2-AR antagonist ICI 118,551. Like MDA-MB-453 cells, ER (-)
MDA-MB-468 cells were affected by all β-AR antagonists indicating expression of both,
β1-and β2-ARs in these cells.
In summary, propranolol was more effective to inhibit DNA synthesis than either
the selective β2-antagonist ICI 118,551 or the selective β1 antagonist atenolol.

ER (+)

cell lines generally were more responsive to the β1-antagonist atenolol whereas ER (-)
cell lines were more responsive to the β2-antagonists ICI 118,551, suggesting that in ER
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(+) cell lines β1-ARs predominate while in ER (-) cell lines β2-ARs predominate.
The β1/2-agonist isoproterenol significantly increased DNA synthesis only in ER
(-) cell lines, with the exception of MDA-MB-468.

The increases in DNA synthesis

were concentration-dependent in MDA-MB-453 cells up to an almost two-fold increase
at the 1 µM concentration of isoproterenol. This finding suggests the presence of β-AR
in this cell line. In the ER (-) cell line MDA-MB-435, a maximum increase in DNA
synthesis was already reached at the lowest concentration (50 nM) of isoproterenol. The
extreme sensitivity of this cell line may be a reflection of over-expressed β-ARs.
Interestingly, these two cell lines did not undergo any receptor desensitization at these
concentrations, suggesting that the β-ARs responded to isoproterenol without intervening
receptor dysregulation.

The MDA-MB-231 cell line responded to isoproterenol

treatment at only low concentrations and the increases in DNA synthesis started to
decline at concentrations above 250 nM of isoproterenol.
regulation of β-ARs by

This may point to a down-

high concentrations of isoproterenol.

In addition, high

concentrations of isoproterenol may nonselectively interact with other growth factors and
their signaling pathways or activate genes that are growth inhibitory.

On the other hand,

the growth stimulatory effects of isoproterenol on the ER (-) cell lines may partly be
explained by the fact that ER (-) breast cancer cell lines express many growth factors on
their membranes and isoproterenol may interact or activate those growth factors, thus
indirectly inducing cell proliferation.
The absence of any growth stimulatory effect of isoproterenol in MDA-MB-468
cells may partly be attributed to relatively low concentrations of isoproterenol used
because this cell line responded very well to all β-AR antagonists.
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It also seems

possible that this cell line expressed constitutively activated β-ARs, which cannot be
further stimulated by agonists but nevertheless respond to antagonists.
No ER (+) cell line responded significantly to isoproterenol treatment. There was
no increase in DNA synthesis in MCF-7 cells in response to any isoproterenol
concentration, while in the two other ER (+) cell lines (MDA-MB-361, ZR-75-1) DNA
synthesis increased only slightly over basal levels.

As these three ER (+) breast cancer

cell lines significantly responded to all β-AR antagonists, they may have already been
maximally stimulated by constitutively activated β-ARs.

It is also possible that the

relatively slow growth rate of ER (+) cell lines in comparison to ER (-) cell lines, may
have required longer exposure times (several days) to yield detectable stimulatory effects.
The release of fatty acids from the plasma membrane by phospholipases might be
increased by several factors, including, growth factors, adrenergic agonists, bradykinin,
ACTH, serotonin, dopamine, angiotensin-II and musacarinic cholinergic agents (83).
Even though fatty acids and specifically AA metabolism have been widely investigated
for over 25 years, the exact mechanisms of action and effect of AA metabolism at the
cellular level still remain to be uncovered.

The release of AA from cellular membranes

generally limits the synthesis of AA metabolites.

AA is the precursor of a large family

of compounds called eicosanoids, consisting of COX- derived PGs and LOX- derived
LTs (22,23,71).
Because the controlled release of AA from the membranes by specific
phospholipases not only is the first step in the production of several eicosanoids but also
is an important aspect of cell signaling, alterations in AA release might be a crucial factor
in many pathological conditions.

The human breast cancer cell line BT-20 has been
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shown to over-express EGF and TGF receptors, and the lipoxygenase inhibitor NDGA,
inhibited DNA synthesis in this cell line (144).

This suggests the possible involvement

of lipoxygenase metabolites or genes modulated by LOX enzymes in tumor formation in
this specific breast cancer line.
AA and its downstream products (eicosanoids) are considered crucial modulators
of several cellular functions because eicosanoids are generally produced on demand by
the rate limiting enzymes. Other than ion channels in which AA and eicosanoids have
important impact, the G- proteins (GTP-binding proteins), a family of transducer
molecules relaying signals from the membrane receptor-ligand interaction to the effector
proteins regulating cellular responses, are also modulated by AA (83,145,146),
suggesting that in addition to its direct action on the production of several mediators, AA
may modulate several signaling pathways regulated by G-proteins. On the other hand, in
platelets, the α subunits of G-proteins are arachidonoylated by post-translational
modifications (146).
In adipose tissue, AA and other fatty acid metabolism are known to be regulated
by c-AMP.

The c-AMP increases PGE2 production, activates NFκB and causes COX-2

mRNA over-expression in macrophages (147).

The n-6 polyunsaturated fatty acids

increased adenylate cyclase in response to isoproterenol in pig adipocytes by enhancing
the affinity of β-ARs for agonists (83).

These findings suggest that the tumor promoting

effects of n-6 dietary fats may partly mediated by an interaction with β-adrenergic
regulatory pathways.

In contrast, AA at concentrations of 100-300 µM decreased PKA

activity in S49 lymphoma cells (83).

This suggests that AA itself can be a protective

factor against tumor progression unless it is metabolized to its downstream effectors.
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This interpretation is supported by a number of studies, which have shown that
exogenous or endogenous AA reduces tumor growth.
The enzyme cPLA2 is involved in receptor activated signaling cascades and is
phosphorylated by MAPK (22,148).

Linoleic acid has a synergistic effect on the EGF-

stimulated growth of mouse mammary epithelial cells in primary culture and it
phosphorylated MAPK protein as well (30,149).

The role of different fatty acids and

particularly AA on tumor progression or initiation has also been attributed to the
enhancer action of AA and free fatty acids (FFA) on PKC activation, because AA causes
a sustained PKC activation in many tumor cells.

PKC is rapidly and transiently

activated by the diacylglycerol (DAG) and Inositol 1,4,5, triphosphate (IP3) – mobilized
intracellular Ca+2 derived from the membrane phospholipids (PIP2) by the activity of PLC
(83). PKC induces the MAPK cascade by activating RAF-1 kinase protein expression.
PKC has also been implicated in the regulation of physiological and pathological
processes, including cell proliferation, growth and differentiation.
Arachidonic acid and other free fatty acids (FFA) in the cytoplasm modulate
several signal transduction pathway molecules, without undergoing metabolic conversion
to the active eicosanoids (83). Several fatty acids, including AA, are considered as both
modulator and second messenger. A modulator is a substance acting in a precise site for
a very short time in a reversible manner to modify the properties and functions of a
signal. Generally, the first messenger, a ligand or an agonist, depending on the cell type
may act at the receptor level to modify several cellular activities. The second messenger,
on the other hand, is generated in response to the first messenger and its concentration is
altered by the primary signal and it may disappear as well as its action associates with the
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physiological effects of the primary signal.

The second messengers relay the first signal

in a sequence of events acting either in the cytoplasm or nucleus in order to regulate
different cellular functions and gene expressions.

Fatty acid generation from the

membrane phospholipids by different phospholipases and in response to c-AMP
production from ATP by the AC enzyme are the examples of second messengers.

Fatty

acids are also modulators since they act in a reversible manner at specific intracellular
sites for a short time to increase or decrease a physiological signal. Fatty acids modify
the effects of several cellular functions, including protein kinases, G-proteins, adenylate
and guanylate cyclases, phospholipases and almost all of the ion channels (82,
83,148,150).
The use of specific and general NSAIDs is being considered as a promising
cancer prevention strategy, because of the documented protective effects of NSAIDs on
cancer progression.

In turn, this effect has been attributed to the inhibition of the PGs

that have been implicated as cofactors in tumor formation and to the induction of cell
cycle arrest and apoptosis (24,151,152) (Figure: 3).

PGE2 production is controlled by

two mechanisms: the regulation of substrate availability, mediated by PLA2 and the
ability of cells to metabolize free AA to PGs, regulated by COX-2. The ER (-) breast
cancer cell line, MDA-MB-231 expresses high levels of PLA2 (153).
In this project, the FLAP inhibitor, MK886, was a very strong inhibitor of DNA
synthesis in all breast cancer cell lines tested.

MK886, a strong inhibitor of leukotriene

synthesis, blocks the translocation of 5-LOX by changing the active site of FLAP (27).
MK-886 was a very potent inhibitor of DNA synthesis for both ER (+) MCF-7 and ER (-)
MDA-MB-453 cell lines.

Even though the inhibition in DNA synthesis was
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concentration-dependent in both cell lines, the ER (-) cell line MDA-MB-453 was much
more responsive to MK-886 treatment.

For the ER (+) MCF-7 breast cancer cell line,

there was almost no difference in the inhibition of DNA synthesis at both 1 and 10 µM
concentrations of MK-886.

This may suggest a relative lack of LOX enzymes in the

ER(+) cells, resulting in saturation of MK-886 binding already at low drug concentration.
Generally, high concentrations of NDGA inhibited DNA synthesis of both ER (+)
and ER (-) cell lines. For the ER (-) cell lines, the first significant inhibition was observed
at 5 µM concentration and continued up to 40 µM concentration.

In the ER (-) MDA-

MB-435 breast cancer cell line, the inhibition in DNA synthesis was considerably more
pronounced than in other ER (-) cell lines. At a 40 µM NDGA concentration, there was
almost complete inhibition of DNA synthesis this cell line. This may implicate a strong
enzyme occupation by the inhibitor NDGA.
In summary, the reduction in DNA synthesis caused by the FLAP inhibitor MK886 and by the non-specific LOX inhibitor NDGA was significantly higher in ER (-) cell
lines than in ER (+) cell lines. This suggests that metastatic and invasive ER (-) breast
cancer cells may over-express the lipoxygenase cascade.

The strong inhibitory effect

on DNA synthesis seen in the presence of both NDGA and MK-886 might be attributed
to the inactivation of mitogenic signaling cascades or of genes driving cells to overgrow
in the presence of LOX protein.
Generally, lower concentrations of NDGA and MK-886 than of the COX
inhibitors were required to reduce DNA synthesis.

Only the highest concentrations of

the COX 1/2 inhibitor aspirin or the specific COX-2 inhibitor meloxicam did
significantly reduce DNA synthesis in both ER (+) and ER (-) breast cancer cells. In the
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ER (-) MDA-MB-453 cell line DNA synthesis was inhibited in a concentrationdependent manner at each concentration of aspirin, while in ER (+) MCF-7 cells the
response reversed at the 1 µM concentration of aspirin.

This difference may partly be

attributed to higher COX-1/2 gene expression levels in the ER (-) breast cancer cell line.
This interpretation is supported by reports that only ER (-) breast cancer cell lines overexpress COX-2.

Like aspirin, the COX-2 specific inhibitor meloxicam caused

significant inhibitions in DNA synthesis of both ER (+) and ER (-) cell lines at only
higher concentrations.

The ER (+) ZR-75-1 and ER (-) MDA-MB-231 cell lines were

significantly more responsive to meloxicam than the other cell lines.
Collectively, these results indicate that the COX pathway in these cell lines was
either at a higher level of activity than the LOX pathway and therefore needed higher
concentrations of inhibitors or that the cells have higher levels of COX protein than 5LOX protein.

On the other hand, the pharmacokinetic and pharmacodynamic

properties of LOX pathway inhibitors might be more potent than COX inhibitors’. The
cell proliferation results obtained in our study are in accord with two recent reports
which showed that MDA-MB-231 breast cancer cells constitutively expressed the COX-2
gene accompanied by elevated PGE2 production (27,91), while MCF-7 and ZR-75-1
have been shown to express only COX-1 but not the COX-2 enzyme (27).
The fact that the 5-LOX inhibitor NDGA significantly inhibited cell proliferation
in both ER (+) and ER (-) breast cancer cell lines whereas the selective COX-2 inhibitor
meloxicam caused significant reduction only at higher concentrations suggests that the
growth of these cells may be more dependent on leukotrienes than prostaglandins. On
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the other hand, the lypoxygenase inhibitors may be more effective tumor suppressive
compounds than the COX-2 inhibitors.
As yet unpublished data from our laboratory have shown that the ER (-) breast
cancer cell line MDA-MB-435 expressed β2-AR as assessed by RT-PCR and that the βAR agonist isoprotorenol, induced AA release in that cell line.

Prospective studies will

be conducted to determine whether or not β-AR –AA dependent growth regulating
pathways modulate the expression of upstream or downstream effectors of both AA and
other signaling cascades and induce transcription factor expression in breast cancer cells.
The expression of the COX-2 gene is rapidly increased by growth factors, tumor
promoters and several cytokines and is markedly induced in a subset of cells including
endothelial cells and colon, stomach, prostate, pancreatic and breast cancer cells
(89,152,154-156). Lysophosphatidylcholine, one of the phospholipids on the cellular
membranes, activated MAPK and transcription factors, CREB and ATF-1 with
concomitant COX-2 over-expression in vascular endothelial cells, indicating that the
activators of membrane phospholipids might induce COX-2 expression together with
other cellular signal transduction elements to stimulate cell growth in many cells (157).
In our study, high concentrations of both the COX 1/2 inhibitor aspirin and the COX-2
specific inhibitor meloxicam, inhibited DNA synthesis in all cell lines studied. Because
in our study the COX 1/2 gene expression profile of the cell lines studied has not been
determined, interpretation of this data is somewhat speculative.
There are a number of cross talks between different signaling cascades and that
some NSAIDs inhibit cell growth and angiogenesis, while inducing apoptosis in a
manner independent from their proposed activity.
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Therefore, it is imperative to take

into account the other actions of specific and general NSAIDs on cell regulation and
control.
The ER (+) cell line MCF-7 and the ER (-) cell line MDA-MB-453 were treated
with the K+1 channel inhibitor quinidine to asses the effects of potassium channels on
DNA synthesis.

Cell proliferation assays showed that quinidine significantly inhibited

DNA synthesis in both cell lines.

Quinidine was used at higher concentrations than β-

AR agonist and antagonists based on effective concentration levels reported in the
literature. The inhibition of DNA synthesis by quinidine was concentration-dependent in
both cell lines. The ER (-) cell line MDA-MB-453 was more sensitive to quinidine than
the ER (+) cell line MCF-7, as reflected by a significant response of MDA-MB-453 cells
to the lowest concentration of quinidine (10 µM).

On the other hand, the lowest

concentration of quinidine to significantly reduce DNA synthesis in MCF-7 cell line was
20 µM.
Because quinidine is a blocker for all K+1 channels, including GIRK1, these data
may indicate the involvement of several different potassium channel in the observed
effect. The response to quinidine may be attributable to the over-expression of GIRK1
gene, because our RT-PCR studies indicate over-expression of GIRK1 in this cell line
(Figure: 14).
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Accordingly, these finding suggest that in addition to their documented

the metastasis and invasion (130), the GIRKs may also directly regulate cell

proliferation and growth in breast cancer cells. The use of novel GIRK1 inhibitors may
thus be useful for the control of cellular growth and metastasis of breast tumors.

The

exact mechanism of action of GIRK1 in breast and other cancers still remains unclear and
needs to be elucidated in the future.
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Growth factors, hormones, receptors, inflammatory mediators and eicosanoids are
considered to play crucial roles in the initiation and maintenance of tumor cell survival
and growth.

In response to the extracellular signals including hormones, growth factors,

cytokines, antigens and endotoxins, the cells activate or inactivate specific transcription
factors or genes in order to regulate diverse cellular processes such as cell proliferation,
differentiation and growth and cellular metabolism.

In order to understand the

underlying mechanisms in the regulation of these cellular processes, the cellular signal
transduction pathways modulating these events have to be elicited (158-161).
The role of signal transduction pathways in cancer formation and cell
transformation is an established concept. In many epithelial cancers, the overexpressed
or mutated receptors with their ligands bound by autocrine or paracrine loops to each
other are the core factors in tumor formation.

For example, EGF receptors regulate

many pathways including Ras, PLC, Src tyrosine kinase, PI3K and protein tyrosine
phosphatases. Ras, activated by EGF, regulates the MAPK (63,162,163).

Signal

transduction between MAPK in the cytoplasm and receptors on the cell membrane
requires a series of events leading first to the formation of the activated Ras-Raf complex
on the membrane, followed by initiation of the cytosolic MEK-MAPK pathway.
The MAPK pathway plays a significant role in the regulation of cellular processes
including gene expression, cell survival, cell growth, apoptosis and cell motility.
Components of the MAPK pathway have been shown to be mediators of phosphorylation
of intracellular substrates including protein kinases, transcription factors and cell growth
regulators (162).

MAPK activity is mediated through three cascades including a

MAPK, MAPK kinase (MAPKK, MKK, MEK) and a MAPKK kinase or MEK kinase
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(MAPKKK or MEKK).

The MAPK family includes at least four different subfamilies

including extracellular signal-related kinases (ERK-1/2), Jun amino-terminal kinases
(JNK1/2/3), p38 proteins (p38 α/β/δ/γ) that are regulated by distinct MAPKKs: MEK1/2
for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK 5 for
ERK5 (158-160). Nevertheless, each of these specific MAPKK might be activated by
more than one MAPKKK, leading to increases in the MAPK diversity (161).
The p38 MAPK and JNK pathways are induced by bacterial endotoxins,
inflammatory cytokines and environmental stress, whereas ERKs are mainly activated by
mitogens of the receptor tyrosine kinase family (163,164).

These kinases are in turn

induced by the upstream mitogen-activated protein / ERK kinases (MEKs) such as
SAPK/ERK kinase-1 (SEK1, also known as MEK4), which is upstream of JNK/SAPK
and MKK3/MKK6, which are upstream of p38 MAPK.

These MEKs are in turn

activated by MEK kinases, which MEKK 1, 2,3 and 5 have been, determined to date
(165).

Once activated, they can phosphorylate and activate a variety of transcription

factors modulating several gene expressions.

The dual phosphorylation of tyrosine (Y

185) and threonine (T 183) residues are required for the activation of the MAPK family
proteins (8,116,117,185, 186).

In the nucleus, most MAPKs phosphorylate Ets

transcription factors (e.g., Elk-1, Cyclin D1, p21) that are involved in the activation of cfos gene, whose products heterodimerize with the Jun proteins to form activator protein 1
(AP-1) complexes.

The enhancing of AP-1 activity by MAPKs results in the cell

proliferation by increasing cyclin D1 induction (159-160).
The inhibition of p38 MAPK by SC68376 inhibited cytokine-induced activation
of COX-2 and PGE2 synthesis in NIH 3T3 cells. (164), suggesting that this pathway may
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be a crucial signaling mechanism modulating cytokine- induced COX-2 gene expression
and PG synthesis because inhibition of MAPK pathway may also inactivate or reduce the
activation of PLA2.

Furthermore, blocking of MEKK1-induced PGE2 production by a

COX-2 inhibitor, NS-398, in NIH 3T3 cells indicating that COX- 2 is an important
mediator in this process and that PLA2 is not the only target in MAPK pathway (164).
MAPK activation assays were performed for 6 and 24 hours because at shorter
time periods no activation has been observed in response to isoproterenol.

For MAPK

studies, 1 µM isoproterenol has been used because it was the most effective concentration
for cell proliferation studies. In MAPK (p44 / p42 ; ERK1 / ERK2 ) activation studies,
our results show that in ER (+) MCF-7 cell line 1 µM isoproterenol slightly activated
(phosphorylated) MAPK protein at 6 hours, but the activation ceased at 24 hours of
exposure. In ER (-) MDA-MB-453 cell line, however, a slight activation in MAPK was
seen at only 24 hours after 1 µM isoproterenol treatment. This may suggest that MAPK
may be constitutively activated in these breast cancer cell lines and may not be affected
by receptor-mediated activation.
The β1/2-AR antagonist 1 µM propranolol caused no significant change in the
activation of MAPK protein in both ER (+) MCF-7 and ER (-) MDA-MB-453 breast
cancer cell lines.

The MEK, the upstream effector of MAPK, may be modulated by

other growth factors or kinases so that the MAPK levels may not be changed in this cell
line.

Because MAPK serves a more common integration point among multiple cell

signaling pathways, it is reasonable that MAPK can be less responsive to a single
inhibitor, propranolol.

In addition, another gene or another signaling pathway may be

influencing the phosphorylation of MAPK in these cell lines, because phosphorylation of
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the appropriate amino acid of the kinase protein is believed to modify the protein and
expose the catalytic domain for subsequent substrate activation (158-160). Therefore, the
discrepancies between the activation and expression of MAPK in response to propranolol
treatment may partly be explained by a mechanism in which propranolol may not
influence the direct phosphorylation of the MAPK during the same interval that it effects
the MAPK expression.
In our studies on MAPK expression, 1 µM propranolol inhibited ERK1/2
expression in the ER (+) MCF-7 cell line at only 150 minutes of exposure while no
significant inhibition in the expression status of MAPK was observed at earlier time
intervals. In ER (-) MDA-MB-453 cells a reduction in the expression of MAPK was
observed at both 60 and 150 minutes of exposure.

The fact that propranolol did not

cause inhibition in the MAPK expression up to 60 and 150 minutes may be attributed to a
lack of effective receptor inhibition by propranolol or an over-abundance of β-ARs in
these cells.

In conjunction with the relatively weak inhibition of MAPK expression

these findings also suggest that pathways other then the MAPK cascade were primarily
affected by propranolol.
The specific β1-AR antagonist atenolol (1 µM) did not change the expression of
MAPK in ER (+) MCF-7 o ER (-) MDA-MB-453 breast cancer cells, suggesting that β1ARs did not signal via the MAPK cascade in these cells and that expression levels of
MAPK protein may be dependent on additional growth factor pathways expressed in
these cells.
The specific β2-AR antagonist ICI 118,551 (1µM) significantly inhibited MAPK
expression only in ER (-) MDA-MB-453 cells at 60 and 150 minutes of exposure.
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There was no significant change in the levels of MAPK expression at other times. In the
ER (+) cell line MCF-7, however, the expression levels of MAPK protein between
treated and control cells remained unchanged after exposure to ICI 118,551.

The

responsiveness of MDA-MB-453 cells to this antagonist reflects the presence of β2-AR in
these cells and suggests that they signal via the MAPK cascade. On the other hand, the
lack of responsiveness of MCF-7 cells may reflect an absence of β2-ARs or constitutively
high levels of expression of MAPK proteins.
The specific COX-2 inhibitor meloxicam was used at a concentration widely
reported in the literature (100 µM), and cells were exposed to it for 24 hours to see its
effects on MAPK expression.

Meloxicam caused a slight decrease in total MAPK

expression only in the ER (+) MCF-7 cells while it inhibited only ERK1 expression in
ER (-) MDA-MB-231 cells.

These findings suggests that meloxicam may utilize the

MAPK cascade of both MCF-7 and MDA-MB-231 cells as a modulator. It also possible
that meloxicam may reduce the production of several prostaglandins such as PGE2 in
tumor cells. PGE2 is an activator of adenylate cyclase, which forms c-AMP from ATP.
The PKA activated by c-AMP up-regulate the MAPK pathway (Figure 5 and 24). The
inhibition of only one isoform of ERK (ERK1) by meloxicam in MDA-MB-231 cells
may have been caused by ERK1 stabilization or high levels of preexisting ERK2 protein.
Other cell lines, including the ER (-) MDA-MB-435 and MDA-MB-468 cell lines, and
the ER (+) cell line ZR-75-1 did not exhibit differences in the expression status of MAPK
in response to meloxicam.

It is highly likely that these cells may be modulated by

growth factors unrelated to the COX-2 enzyme. Interestingly, in one of the ER (-) cell
lines (MDA-MB-453) meloxicam increased MAPK expression levels.
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This cell line

may have other growth factor receptors or genes that can be activated by COX-2
inhibitors, or COX-2 independent mechanism may be responsible for this effect.
The non-specific LOX inhibitor NDGA was used at 30 µM concentration in
accordance with published procedures.

In three ER (-) cell lines, MAPK expression was

decreased by NDGA treatment. In the ER (-) cell lines MDA-MB-435 and MDA-MB231, total MAPK expression was inhibited at 24 hours of exposure to NDGA, while in
MDA-MB-468 cells, only the ERK1 isoform of MAPK was inhibited.
indicate that leukotrienes formed by

These findings

LOX enzymes from AA may modulate the

expression of MAPK in these cancer cells and is in accord with the often observed
overexpression of LOX in breast cancer.
The ER (-) cell line MDA-MB-453 and two ER (+) cell lines (MCF-7 and ZR-751) did not respond to NDGA by changes in the expression of MAPK.

This may reflect

high base levels of MAPK protein expression that cannot be altered by NDGA or points
to the influence of other non-NDGA -associated pathways effecting MAPK in these cells.
The changes in the expression of level MAPK protein by these inhibitors may
partly be attributed to the increased levels of free AA in the cytoplasm. AA may inhibit
the expression levels of MAPK, or reduced level of PGs and LTs may be responsible for
the MAPK inhibition. On the other hand, when β-adrenergic antagonists are present, the
decrease in PKA or c-AMP levels may directly or indirectly decrease the levels of MAPK
protein.
Inhibition of the total (ERK1 and ERK2) MAPK protein expression levels by
COX-2 inhibitors, 5-LOX inhibitors and β-adrenergic receptor antagonists without
changes in the phosphorylation levels of ERK1 and ERK2 suggests that these inhibitors
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are probably modulating the transcriptional expression of MAPK proteins with no effect
either on the phosphorylation status of MAPK proteins or on the translation (mRNA)
level of MAPK protein.

This interpretation is in accord with reports that many post-

translational modifications may occur at the protein level to decrease or modify the
expected effect of any drug (159,161).
Overexpression of COX-2 during angiogenesis or neovascularization of many
human epithelial cancers seems to be a characteristic feature of these cancers.

The

formation of new blood vessels by angiogenesis is a major requirement for the growth
and metastatic spread of many tumors and NSAIDs have been shown to inhibit
angiogenesis.

COX-1 was necessary for the formation of endothelial tubes while COX-

2 was required for the production of VEGF, one of the angiogenic factors (152),
suggesting that in addition to their role in PG metabolisms, NSAIDs inhibiting both
COX-1 and COX-2 may be crucial anti-angiogenic compounds that can prevent
angiogenesis as well as metastasis.

Masferrer et al. stated that mature blood vessels

express COX-1, whereas newly formed cells express inducible COX-2, suggesting that
several tumor-derived growth factors enhance angiogenesis by inducing the production of
COX-2 –derived PGE2 (101,166).

The levels of PGs synthesized by the COXs are

increased in various cancers, including breast cancer and colon cancer. In addition, there
are increased levels of PGE2 in the blood of cancer patients. (23,24,166).
PGE2 induces most of these effects through receptor-mediated elevation of cAMP (116). Chemicals that inhibit PGE2 synthesis have been shown to block PGE2induced c-AMP elevation in tumor cells (167).

Because PGE2 has been shown to be

secreted by both spontaneous and experimentally induced breast cancers and PGE2
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receptors have been found in these cancer cells (167), the anti-proliferative effects of β2AR blockers observed in our studies may have been caused by the inhibition of both
COX- 2 and PGE2 synthesis.

In many cancer cell lines, blockers of lipoxygenase

enzymes were more potent inhibitors of proliferation than blockers of cyclooxygenases.
Even though the mechanism by which COX-2 initiates tumor formation or causes
growth and proliferation of tumor cells has not been exactly explained, DNA oxidation
by COX-2 has been considered by some investigators as a crucial early step in tumor
initiation since COX-2 reactions involve the formation of free oxygen radicals that may
potentially damage cellular macromolecules, including DNA. During the production of
PGG2 from the AA, peroxyl radicals, which are a source of activated oxygen and might
contribute to oxidation of other molecules, are produced and they may attack DNA
causing mutation (168).

Accordingly, COX-2-induced formation of reactive oxygen

radicals were inhibited by both the NSAIDs and antioxidants, including phenol, ascorbic
acid and dopamine (168,169).

These findings suggest that over-activation of AA

metabolism in the course of tumor induction may cause a genotoxic potential that
promotes their progression to malignancy, because the free radicals COX-2 generates
induces DNA mutations.
Receptors that initiate signal transduction pathways are activated by highly
specific interactions with their specific ligands, leading to various biological responses
including protein activation and gene expression. Nevertheless, transactivation or crosstalk between structurally unrelated receptors may occur and one receptor (GPCR or PG
receptors) may modulate the activation or inhibition of another receptor (EGF) (Figure
24) (102,159).
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Figure 24: The cross-talk between signaling pathways. An example of how cross-talk
structurally unrelated receptors may occur and how one receptor (GPCR) can modulate
the activation or inhibition of another receptor (EGF).
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Different signals may lead to an analogous response through similar components
whereas stimulation of a cell with one specific ligand may cause more than one response.
It has been shown that various extracellular stimuli, unrelated to the EGF-like ligands,
may also induce the EGF receptor causing mitogenic responses (159).

The inhibition of

the MAPK pathway by beta-antagonists, 5-LOX and COX-2 antagonists observed by us
may be partly explained by this kind of cross-talk among beta-ARs and the EGF and
prostanoids receptors.
Unlike the RTKs (receptor tyrosine kinases), which include EGF, PDGF and
insulin receptors with a catalytic activity to phosphorylate their targets, the GPCRs have
no intrinsic enzymatic activity.

Agonist activation of GPCRs leads to the induction of a

wide variety of intracellular signaling cascades including modulation of adenylyl cyclases
(AC), MAPKs, phospholipases, and ion channels (Figure: 5,6).

GPCRs contain

adrenergic, muscarinic, dopamine, adenosine, thrombin, serotonin, angiotensin II,
extracellular Ca+2, lysophosphatidic acid (LPA), yeast mating factor and Dictyostelium cAMP receptors (102).

Upon ligand binding, the GPCR undergoes a conformational

change, which dramatically enhances its interaction with the G-protein (Figure 4). The
heterotrimeric G-protein contains three kinds of subunits: α, β and γ.
having a GTPase activity binds to the G-nucleotide.

The α subunit

The β/γ complex acts together as

an inseparable unit enhancing receptor interaction with α subunits.

Ligand binding to

GPCR exchanges bound GDP for GTP resulting in the dissociation of the GTP-bound α
subunit form β/γ subunit.
channels.

The active GTP/α then regulates effector enzymes and ion

The β/γ complex also regulates effector proteins.

The intrinsic GTPase

activity of the α subunit ceases this signaling, and the α subunit then reunites with the β/γ
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subunits so that the resting state is reached again (103). In the absence of activated
receptors, the G-proteins stay predominantly in the inactive GDP state. The enzyme AC,
which is mainly activated by the stimulatory α subunits (Gαs), leads to the production of
c-AMP (206).

However, PLC-β is stimulated to various extents by the Gαq and Gβ/γ

subunits and PKA can specifically inhibit Gβ/γ -induced PLC- β (66).
GPCRs can be desensitized by both uncoupling from their G-proteins and
internalization. Long-term agonist-stimulated β2AR down-regulation contributes to the
receptor desensitization and rapid inactivation causing receptor uncoupling.

This

process is initiated by phosphorylation of the agonist-occupied receptor (170).
Desensitization effectively ceases the physiological effects of β-agonists in normal cells.
Interestingly, GPCR endocytosis is needed for the β2-adrenergic receptor-dependent
induction of the MAPK pathway (171,172).

Both receptors and G-proteins are the

targets for the desensitization in which the different pathways have been well
characterized.

After a few minutes of incubation with the agonist, βARs are

phosphorylated by PKA and GRKs (G-protein-coupled receptor kinases) or βARKs,
leading to functional uncoupling of the receptor from the G-protein (110,171-175).
When receptor stimulation is constant for a longer time, receptor down-regulation
contributes to the strengthening of desensitization through the degradation of pre-existing
receptors and destabilization of receptor mRNA (104,110,113,170).

The

phosphorylation of β2AR by GRK promotes the binding of β-arrestin to the receptor
causing receptor internalization and blocking any further coupling to GS (171, 172).
Cancer cells that respond to long-term agonists stimulation, may loss their response to the
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receptor desensitization and down-regulation and have distinct molecular characteristics
and properties against stimulator and inhibitors resulting in aberrant cellular responses
observed in many cancer cells. In other words, in these kinds of cancer cells, increased
receptors recycling and decreased down-regulation of receptors may occur so that
sustained activation of the receptors resulting in increased stimulation of downstream
effectors may occur.
The β2-Adrenergic receptors (β2-ARs) are one of the G-protein coupled receptors
mediating the effects of catecholamines and growth factors in a variety of cells. Many
cell types are regulated by the distinct actions of β2-ARs.

The β2-AR has an

extracellular amino terminus, seven transmembrane spanning domains and an
intracellular carboxyl terminus.

The gene encoding β2-AR has no intron and is located

on chromosome 5q31-32 (105-108,113-115).

Among the signaling pathways activated

by the β2-AR is the adenylyl cyclase/cAMP pathway (Figure: 4 and 6). c-AMP has been
implicated in the modulation of a number of cellular functions including the control of
cell growth and intracellular Ca+2 concentration.

Depending on the type of cancer,

cAMP may either stimulate or inhibit cell proliferation (61,66,105-107,109,142,176-182).
Cyclic AMP can modulate breast cancer proliferation through a variety of
mechanisms. Cyclic AMP may regulate cell growth by binding to the regulatory subunits
of the c-AMP dependent protein kinase (PKA).

There are two main classes of PKA,

PKAI (type I) and PKAII (type II), which have similar catalytic subunits but different
regulatory subunits, termed RI and RII (183). Tumor specimens and some human cancer
cell lines including breast cancer cell lines over-express only PKAI and / or its RI
regulatory subunit, a phenomenon that has been related with tumor growth (184,185).
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RI is also up-regulated during growth factor–mediated cell transformation (185).
Furthermore, the c-AMP analog 8-Cl-cAMP, an RII site – specific analogue that downregulates RI and suppresses the proliferation of several cancer cells, reduced cell growth
in MCF-7 and MDA-MB-231 breast cancer cell lines as well as decreased the expression
of the ras oncogene (180).
In contrast to the β-antagonists which inhibit cell growth, the β-AR agonist
isoproterenol inhibited DNA synthesis of PC-3 prostate cancer cells and highly metastatic
MDA-MB-231 breast cancer cells (186,187).

Direct administration of membrane

permeable c-AMP analogs resistant to degradation by phosphodiesterases also inhibited
tumorigenesis of MCF-7 breast cancer cells (187), suggesting down-regulation of β2-AR /
cAMP resulting in a reversal of the agonist action observed in our studies. Furthermore,
the actions of β-agonists in these cells in different laboratories may vary depending on
variations in intracellular Ca+2 levels or K+1 channels, which have been implicated in
intracellular signaling of β-ARs. Up-regulated PKA phosphorylates the β2AR resulting
in a switch in the coupling of receptor from GS to GI (188), which might be responsible
for the reported βAR inactivation and subsequent cell growth inhibition by β-AR
agonists.
GIRK channels regulate the cell membrane potential as well as the frequency and
duration of electrical impulses.

Inhibition of GIRK channel activity may influence

cardiac and brain function negatively.

The G protein-linked receptor subtypes that

activate these channels include muscarinic, GABA, serotonin (5HT1A), adenosine (P1),
somatostatin, enkephalin,
(117).

2-adrenergic,

β2-adrenergic and dopamine (D2) receptors

GIRK1 is activated by a variety of hormone and neurotransmitters including
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epinephrine, norepinephrine, 5-HT, dopamine, GABA, adenosine, opioids, acetylcholine
and somatostatin (120).
We selected the ER (-) cell line MDA-MB-453 to investigate the expression status
of GIRK1 in control and propranolol-exposed cells by relative competitive RT-PCR.
GIRK1 was over-expressed when the cells were exposed continuously to propranolol for
7 days.

However, expression levels of GIRK1 remained unchanged when the cells were

treated with propranolol for 30 minutes every day for a 7-day period.

The over-

expression of GIRK1 observed after continuous exposure to propranolol may be
attributable to up-regulation of β-ARs in response to chronic exposure to the β-ARantagonist. In one study, GIRK1 was over-expressed in breast tumor tissues associated
with lymph node metastases.
tissue.

GIRK1 was not expressed in the adjacent normal breast

It was also shown that GIRK1 was over-expressed in the corresponding lymph

node only if the primary tumor over-expressed GIRK1 (130). This study suggests that
GIRK1 might be a crucial marker for the identification of highly aggressive, metastatic
breast cancer and may play a role in the growth regulation of these cancers that may be
targeted for cancer preventive and therapeutic strategies.
The GIRK channel has a conserved peptide sequence, arginine-glycine-aspartate
(RGD), to which another class of membrane proteins, integrins, may bind. The mutation
of this recognition site on the channel blocks this binding, and without this binding, the
GIRK current is reduced or stopped (189).
functions,

including

cell

adhesion,

Because integrins have a wide variety of

migration,

survival,

growth,

proliferation,

differentiation, and modulation of gene expression, the integrin-GIRK interaction might
be important in cell migration and signal transduction pathways.
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Integrin signaling has

been associated with gene activation, src tyrosine kinases, MAPKs and focal adhesion
kinases.

The overexpression of GIRK1 in the invasive breast cancers may partly be

explained by this GIRK – integrin interactions due to the fact that integrins are needed for
cancer cells to metastasize and migrate to the distant organs.

In fact, in neuroblastoma

cell lines, the cell migration and neurite formation have been associated with integrin,
with the activation of a GIRK channel, and with tyrosine phosphorylation (189). With
respect to our studies, over-expression of GIRK may also be associated with modulations
in β-ARs and their associated signal transduction pathways.
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CHAPTER 4: CONCLUSION / SUMMARY
The identification of crucial sites and detailed knowledge of receptor-activated
down-stream events in growth-regulating signal transduction pathways of breast cancer
cells provides a basis for the development of novel therapeutic strategies by targeting
specific components of a given signal transduction pathway.

Understanding the

biochemistry and physiology of a pathway or a specific gene important for cancer
progression or prevention will provide many opportunities for enhanced clinical
management of cancer patients who are at high risk because they have mutations in these
genes or proteins that regulate several crucial pathways.

Modern drug development

strategies thus involve the identification of enzymatic steps that can be inhibited by a
pharmaceutical agent, protein-protein interactions that may be changed, or proteinsignaling molecule interactions that may be appropriately mimicked or suppressed by a
drug. This approach may allow to block tumor cell proliferation, inhibition of gene or
protein expression, stimulation of apoptosis, inactivation of the cell cycle, as well as
inhibition of angiogenesis and metastasis.
Data generated by this study suggest that β-AR, K+1 channel, COX-1/2, FLAP
and 5-LOX antagonists,- dependent on the cell type and concentrations-, decrease cell
proliferation in vitro in both ER (-) and (+) breast cancer cell lines, indicating that these
agents may be valuable tools for the control or inhibition of breast cancer growth.
Among the β-antagonists, propranolol was more effective than the selective β2-antagonist
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ICI 118,551 or the β1-antagonist atenolol.

ER (+) cell lines were generally more

responsive to the β1-antagonist atenolol, whereas ER (-) cell lines were more responsive
to the β2-antagonists ICI 118,551. These findings suggests that in the ER (+) cell lines
β1-ARs predominate while in the ER (-) cell lines the majority of β-ARs were of the β2tye. The reduction in DNA synthesis caused by the FLAP inhibitor MK-886 and the 5LOX inhibitor NDGA was significantly higher in ER (-) cell lines than in the ER (+) cell
lines. On the other hand, the β-agonist isoproterenol significantly increased DNA
synthesis only in ER (-) cell lines, suggesting that in the non-responsive cell lines β-ARs
may have been constitutively activated resulting in maximum growth stimulation without
the addition of external stimuli.
The observed ability of COX inhibitors, 5-LOX inhibitors, β-adrenergic blockers
and K+ channel blockers to suppress the growth and proliferation of the a subset of breast
cancer cells lines is an important finding that provides the basis for the exploration of
such agents in the clinical management and prevention of breast cancer.

Because these

inhibitors are already widely used for the treatment of various diseases they can
immediately be used in clinical trials with breast cancer patients. In particular the β-ARs
represent a promising new target for the development of new drug candidates with
potential application in the clinical fields because a wealth of information is already
available on the biochemical and molecular events underlying signaling by these
receptors.
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